CA2490060A1 - Enhanced phospholipid reduction and calcification mitigation of biological materials - Google Patents
Enhanced phospholipid reduction and calcification mitigation of biological materials Download PDFInfo
- Publication number
- CA2490060A1 CA2490060A1 CA002490060A CA2490060A CA2490060A1 CA 2490060 A1 CA2490060 A1 CA 2490060A1 CA 002490060 A CA002490060 A CA 002490060A CA 2490060 A CA2490060 A CA 2490060A CA 2490060 A1 CA2490060 A1 CA 2490060A1
- Authority
- CA
- Canada
- Prior art keywords
- biological material
- leaflets
- tissue
- preparation
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002308 calcification Effects 0.000 title claims abstract description 78
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 48
- 230000000116 mitigating effect Effects 0.000 title claims abstract description 29
- 239000012620 biological material Substances 0.000 title claims description 140
- 230000009467 reduction Effects 0.000 title description 25
- 238000000034 method Methods 0.000 claims abstract description 201
- 239000004094 surface-active agent Substances 0.000 claims abstract description 74
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 65
- 239000003398 denaturant Substances 0.000 claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims description 94
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 88
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 66
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 43
- 229920000053 polysorbate 80 Polymers 0.000 claims description 43
- 230000001954 sterilising effect Effects 0.000 claims description 23
- 238000004659 sterilization and disinfection Methods 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 19
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 19
- 150000001299 aldehydes Chemical class 0.000 claims description 18
- -1 maleimide compound Chemical class 0.000 claims description 11
- 230000001588 bifunctional effect Effects 0.000 claims description 10
- 239000002736 nonionic surfactant Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- 150000001718 carbodiimides Chemical class 0.000 claims description 3
- 125000005442 diisocyanate group Chemical group 0.000 claims description 3
- 239000003586 protic polar solvent Substances 0.000 claims description 3
- 239000004971 Cross linker Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 42
- 238000002513 implantation Methods 0.000 abstract description 16
- 238000010348 incorporation Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 155
- 239000000243 solution Substances 0.000 description 141
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 86
- 208000004434 Calcinosis Diseases 0.000 description 70
- 239000011575 calcium Substances 0.000 description 61
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 43
- 229910052791 calcium Inorganic materials 0.000 description 43
- 239000008363 phosphate buffer Substances 0.000 description 40
- 229920000136 polysorbate Polymers 0.000 description 38
- 239000003125 aqueous solvent Substances 0.000 description 37
- 235000019441 ethanol Nutrition 0.000 description 32
- 230000008569 process Effects 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 21
- 210000003709 heart valve Anatomy 0.000 description 18
- 238000011946 reduction process Methods 0.000 description 16
- 238000012453 sprague-dawley rat model Methods 0.000 description 16
- 241000283690 Bos taurus Species 0.000 description 15
- 238000004886 process control Methods 0.000 description 15
- 239000012487 rinsing solution Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 238000010561 standard procedure Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000007654 immersion Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000013043 chemical agent Substances 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 239000010432 diamond Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000003516 pericardium Anatomy 0.000 description 5
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 229910003460 diamond Inorganic materials 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008098 formaldehyde solution Substances 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- BYGQBDHUGHBGMD-UHFFFAOYSA-N 2-methylbutanal Chemical compound CCC(C)C=O BYGQBDHUGHBGMD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 2
- 229920002085 Dialdehyde starch Polymers 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000001893 (2R)-2-methylbutanal Substances 0.000 description 1
- 229940031723 1,2-octanediol Drugs 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QQHITEBEBQNARV-UHFFFAOYSA-N 3-[[2-carboxy-2-(2,5-dioxopyrrolidin-1-yl)-2-sulfoethyl]disulfanyl]-2-(2,5-dioxopyrrolidin-1-yl)-2-sulfopropanoic acid Chemical compound O=C1CCC(=O)N1C(S(O)(=O)=O)(C(=O)O)CSSCC(S(O)(=O)=O)(C(O)=O)N1C(=O)CCC1=O QQHITEBEBQNARV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- LNQHREYHFRFJAU-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) pentanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(=O)ON1C(=O)CCC1=O LNQHREYHFRFJAU-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical compound O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical class [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical class OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000002073 venous valve Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/505—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/143—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
There is a need in the tissue treatment arts of methods for effectively mitigating calcification, reducing calcification and reducing phospholipid content of implanted bioprosthetic tissues. The invention provides an effective protocol for preparing biological tissue for incorporation as a bioprosthetic device. Disclosed herein is the discovery that calcification of biological tissue is mitigated and phospholipid content is reduced by including a step in the pre-implantation protocol whereby the biological tissue is treated with a surfactant and cross linking agent in the absence of a denaturant. Furthermore, the biological tissues prepared under this protocol are well suited for use in bioprosthetic devices.
Description
ENHANCED PHOSPHOLIPID REDUCTION AND
CALCIFICATION MITIGATION OF BIOLOGICAL
MATERIALS
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority to commonly assigned U.S.
provisional patent application number 60/396,879 filed July 16, 2002, which is incorporated herein by reference in its entirety for all purposes.
BACKGROUND OF THE INVENTION
CALCIFICATION MITIGATION OF BIOLOGICAL
MATERIALS
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority to commonly assigned U.S.
provisional patent application number 60/396,879 filed July 16, 2002, which is incorporated herein by reference in its entirety for all purposes.
BACKGROUND OF THE INVENTION
[0002] Implantation of medical devices into humans and other animals is carried out with increasing frequency. Implantable medical devices may be formed wholly or partially of biological tissue that has been chemically "fixed"
or preserved. The technique used for chemical fixation of biological tissues typically requires exposure of the biological tissue to one or more chemical agents that are capable of forming cross-linkages between connective tissue protein molecules present in the tissue. Examples of fixed biological tissues that have been used to form implantable bioprostheses include cardiac valves, blood vessels, skin, dura mater, pericardium, ligaments and tendons.
or preserved. The technique used for chemical fixation of biological tissues typically requires exposure of the biological tissue to one or more chemical agents that are capable of forming cross-linkages between connective tissue protein molecules present in the tissue. Examples of fixed biological tissues that have been used to form implantable bioprostheses include cardiac valves, blood vessels, skin, dura mater, pericardium, ligaments and tendons.
[0003] The heart valve is one of the most widely studied implantable prosthesis and its clinical application and pathology are well documented (Schoen et al., Cardiovascular Pathology 1:29-52 (1992)). More than 100,000 cardiac valve prostheses are placed in patients each year (Levy, et al., U.S.
Patent Number 5,674,29). The most common bioprosthetic heart valves in current use around the world are made of porcine aortic tissue or bovine pericardium tissue (Seifter, et al., U.S. Patent Number 5,476,516).
Patent Number 5,674,29). The most common bioprosthetic heart valves in current use around the world are made of porcine aortic tissue or bovine pericardium tissue (Seifter, et al., U.S. Patent Number 5,476,516).
[0004] Biological tissues, including porcine aortic and bovine pericardium tissue, typically contain connective tissue proteins (i.e., collagen and elastin), which act as the supportive framework of the tissue. The pliability or rigidity of each biological tissue is largely determined by the relative amounts of collagen and elastin present within the tissue and/or by the physical structure and conformation of its connective tissue frame work. Each collagen molecule is made up of three polypeptide chains intertwined in a coiled helical conformation.
[0005] To stabilize the bioprosthetic tissue, the reactive moieties of the tissue are blocked by process known as fixation. In 1968, it was found that collagen was stabilized by aldehydes (Nimni et al., J. Biol. Chem. 243:1457-1466 (1968)). Aldehydes stabilize collagen by forming chemical cross-linkages between the polypeptide chains within a given collagen molecule (i.e., intramolecular crosslinkages), or between adjacent collagen molecules (i.e., intermolecular crosslinkages). Today, various chemical fixative agents, sometimes referred to as tanning agents are known in the art. Fixative agents that have been utilized to cross-link collagenous biological tissues include aldehydes (e.g., formaldehyde, glutaraldehyde, dialdehyde starch, para formaldehyde, glyceraldehyde, glyoxal acetaldehyde, acrolein), diisocyanates (e.g., hexamethylene diisocyanate), carbodiimides, and certain polyepoxy compounds (e.g., Denacol-810, -512, or related compounds). Photooxidation has also been used to fix biological tissue.
[0006] Of the various chemical fixatives available, glutaraldehyde is used as the fixative for many commercially available bioprosthetic products, including porcine bioprosthetic heart valves (i.e., the Carpentier-EdwardsT"' stented porcine bioprosthesis; Edwards Lifesciences, Irvine, Cali~ 92614), bovine pericardial heart valve prostheses (e.g., Carpentier-EdwardsT"~ Perimount Pericardial Bioprosthesis, Edwards Lifesciences; Irvine, Calif. 92614) and stentless porcine aortic prostheses (e.g., EdwardsT"' PRIMA Plus Stentless Aortic Bioprosthesis, Edwards Lifesciences, Irvine, Calif. 92614).
[0007] A primary failure mode of bioprosthetic tissue implantation, including both porcine and pericardial biological replacement heart valves, is tissue calcification. For example, calcification causes more than 50 percent of heart valve bioprostheses failures within 10 years of implantation (Schoen et al., Cardiovascular Pathology 1:29-52 (1992)). In addition, calcification proceeds more rapidly in children than in adults (Id.). Morphological examination of explanted bioprostheses indicates that calcification is frequently associated with collagen fibrils, organelles such as mitochondria and nuclei of devitalized cells (including connective tissue cells of the leaflets, and cells of the muscle shelf, and aortic wall of porcine aortic valves), thrombi, and vegetations (Schoen FJ, et al., J Card Surg 9[suppl]:222-227 (1994); Schoen FJ, et al., J. Biomed.
Mater. Res. 47:439-465 (1999); Ferrans YJ, et al., Hum Pathol 18:586-595 (1987)). Although the calcification process itself has been studied extensively, the mechanism of tissue calcification remains unclear.
Mater. Res. 47:439-465 (1999); Ferrans YJ, et al., Hum Pathol 18:586-595 (1987)). Although the calcification process itself has been studied extensively, the mechanism of tissue calcification remains unclear.
[0008] Calcification can result in undesirable stiffening or degradation of the bioprosthesis. Two types of calcification-intrinsic and extrinsic--are known to occur in fixed collagenous bioprostheses. Intrinsic calcification is characterized by the precipitation of calcium and phosphate ions within the fixed bioprosthetic tissue, including the collagen matrix and remnant cells.
Extrinsic calcification is characterized by the precipitation of calcium and phosphate ions within the thrombus, including adherent cells (e.g., platelets) that adhere to the bioprosthesis and the development of calcium phosphate-containing surface plaques on the bioprosthesis.
Extrinsic calcification is characterized by the precipitation of calcium and phosphate ions within the thrombus, including adherent cells (e.g., platelets) that adhere to the bioprosthesis and the development of calcium phosphate-containing surface plaques on the bioprosthesis.
[0009] The factors that affect the rate at which fixed tissue bioprostheses undergo calcification have not been fully elucidated. However, factors that are thought to influence the rate of calcification include:
a) patient's age;
b) existing metabolic disorders (i.e., c) hypercalcemia, diabetes, etc.);
d) dietary factors;
e) infection;
f) parenteral calcium administration;
g) dehydration;
h) distortion/mechanical factors;
i) inadequate coagulation therapy during initial period following surgical implantation; and j) host tissue responses.
a) patient's age;
b) existing metabolic disorders (i.e., c) hypercalcemia, diabetes, etc.);
d) dietary factors;
e) infection;
f) parenteral calcium administration;
g) dehydration;
h) distortion/mechanical factors;
i) inadequate coagulation therapy during initial period following surgical implantation; and j) host tissue responses.
[0010] The factors that are thought to affect the propensity for platelets to adhere to a fixed bioprosthetic tissue include:
a) tissue damage;
b) diet;
c) surface properties of the tissue, including the nature of exposed collagen (e.g., type I, IV, etc.);
d) metabolic changes;
e) coagulation;
f) hemodynamics g) inflammation; and, h) infection.
a) tissue damage;
b) diet;
c) surface properties of the tissue, including the nature of exposed collagen (e.g., type I, IV, etc.);
d) metabolic changes;
e) coagulation;
f) hemodynamics g) inflammation; and, h) infection.
[0011] Various techniques have heretofore been proposed for reducing the in situ calcification of glutaraldehyde-fixed bioprostheses. Included among these calcification reduction techniques are the methods described in Nashef et al., U.S. Patent Number 4,885,005; Carpentier et al., U.S. Patent Number 4,648,881; Girardot et al., U.S. Patent Number 4,976,733; Carpentier et al., U.S.
Patent Number 5,002,2566; Pollock et al., EP 103947A2; Nashef et al., U.S.
Patent Number 4,885,005, Cunanan et al., U.S. Patent Number 6,214,054, and Cunanan et al., U.S. Patent Application Number 09/693,186, which are herein incorporated by reference in their entirety for all purposes.
Patent Number 5,002,2566; Pollock et al., EP 103947A2; Nashef et al., U.S.
Patent Number 4,885,005, Cunanan et al., U.S. Patent Number 6,214,054, and Cunanan et al., U.S. Patent Application Number 09/693,186, which are herein incorporated by reference in their entirety for all purposes.
[0012] However, there continues to be a need in the art for methods for producing a bioprosthesis resistant to undesirable stiffening or degradation.
The present invention meets these and other needs.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention meets these and other needs.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 provides data from experiments to assess 90-day rat subcutaneous pericardial leaflet calcification (pg Ca/mg dry wt) as described in Example 1 below.
5 [0014] Figure 2 illustrates data from experiments to assess 90-day rat subcutaneous pericardial leaflet calcification (pg Ca/mg dry wt) as described in Example 1 below.
[0015] Figure 3 provides data from experiments to assess rat 90-day subcutaneous porcine leaflet calcification (fig Ca/mg dry wt) as described in Example 2 below.
[0016] Figure 4 illustrates data from experiments to assess 90-day rat subcutaneous porcine leaflet calcification (pg Ca/mg dry wt) as described in Example 2 below.
BRIEF SUMMARY OF THE INVENTION
[0017] The present invention provides methods of producing superior biological materials for implantation by mitigating calcification, reducing calcification, and/or reducing phospholipid content in the biological materials upon implantation. The procedures provide biological tissues that are well suited for use in bioprosthetic devices. The invention further provides superior biological materials prepared in accordance with the methods of the invention, and implantable prosthetics that comprise such superior biological materials.
[0018] Thus, in a first aspect, the present invention provides a method of treating a biological material, which comprises contacting the biological material with a preparation that contains a cross linking agent and a surfactant.
The preparation does not contain a denaturant.
[0019] In a second aspect, the present invention provides a method of treating a biological material, which comprises the step of contacting the biological material with a preparation having a surfactant and a cross linking agent in the absence of a denaturant (hereinafter referred to as the SCL step); and the step of contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant (hereinafter referred to as the SCLD
step).
[0020] In a third aspect, the present invention provides a method of treating a biological material that comprises four separate steps performed in a specified sequence. In step one, the biological material is contacted with a preparation containing a cross linking agent in the absence of denaturant and surfactant.
After step one, step two is performed, which comprises contacting the biological material with a preparation containing a cross linking agent and a surfactant in the absence of denaturant. After step two, step three is performed, which comprises contacting the biological material with a preparation containing a cross linking agent, a denaturant and a surfactant. After step three, the biological material is contacted with a terminal liquid sterilization solution.
[0021] In a fourth aspect, the present invention provides a method of treating a biological material that comprises contacting the biological material with a preparation having a cross linking agent and a surfactant in the absence of a denaturant. The method results in mitigation of calcification of the biological material upon implantation into a host organism relative to an identical method of treating the biological material with the exception that the biological material is not contacted with a preparation having a cross linking agent and a surfactant in the absence of a denaturant.
[0022] In a fifth aspect, the present invention provides a method of treating a biological material that comprises contacting the biological material with a preparation having a cross linking agent and a surfactant in the absence of a denaturant. The method results in reduction of phospholipid content of the biological material upon implantation into a host organism relative to an identical method of treating the biological material with the exception that the biological material is not contacted with a preparation having a cross linking agent and a surfactant in the absence of a denaturant.
[0023] In a sixth aspect, the present invention provides a method of treating a biological material that comprises contacting the biological material with a S preparation having a cross linking agent and a surfactant in the absence of a denaturant. The method results in reduction of calcium content of the biological material upon implantation into a host organism relative to an identical method of treating the biological material with the exception that the biological material is not contacted with a preparation having a cross linking agent and a surfactant in the absence of a denaturant.
[0024] In a seventh embodiment, the present invention provides a biological material resistant to calcification produced by a method of treating the biological material comprising the step of contacting the biological material with a preparation comprising a surfactant and a cross linking agent in the absence of a denaturant; and the step of contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant.
[0025] These and other embodiments and advantages of the present invention will be apparent from the detailed description that follows.
DETAILED DESCRIPTION OF THE INVENTION
METHODS OF MITIGATING OR REDUCING CALCIFICATION
[0026] In one aspect, the present invention provides superior methods of treating a biological material, wherein the treatment mitigates calcification when the biological material is implanted into a host organism. The methods of treatment to mitigate calcification are also referred to herein as methods of mitigating calcification of a biological tissue. The methods of the present invention mitigate calcification of a biological material relative to methods that are identical with the exception that the SCL step is not performed.
Individual steps of the methods of the present invention are described in detail below.
[0027] Mitigation of calcification refers to reducing the incidence of calcification. The incidence of calcification refers to the number of members of a population of implanted biological materials for which calcification occurs relative to the total number of members of the population. Elimination of calcification means mitigating calcification wherein no members of a population of implanted biological materials are calcified.
[0028] An exemplary calcification is the accumulation of calcium su~cient to cause stiffening or degradation of biological tissue implanted into a host organism. A variety of techniques are useful in measuring calcification in a biological material after implantation. In an exemplary assay, calcification is measured by implanting the biological material in a host organism for a period of time, removing the implanted biological material, and measuring the calcium levels in the biological material. The biological material may be implanted subcutaneously or intramuscularly in, for example, a mammalian host organism between 10 and 100 days. The mammalian host organism may be any appropriate species, such as a rat or a rabbit.
[0029] Another exemplary calcification is the measurement of calcium accumulation after implantation of the biological material into a mammalian host organism for 30 to 90 days. The biological material is then removed and analyzed for calcium content. Surprisingly, in this example, biological material containing calcium levels below S pg of calcium per mg of dried material (hereinafter referred to as p.g Ca/mg) have superior mechanical properties, enhanced longevity and durability, and increased resistance to failure when used as bioprosthetic tissue compared to biological materials containing more than pg Ca/mg. Conversely, biological material containing calcium levels above 5 pg Ca/mg have inferior mechanical properties, decreased durability, and increased rates of failure when used as bioprosthetic tissue. Therefore, in this example, bioprosthetic or biological tissue containing calcium content above 5 pg Ca/mg tissue is considered calcified whereas bioprosthetic or biological tissue containing calcium content below 5 ~.g Ca/mg tissue is considered not calcified. Thus, in this example, mitigation of calcification is defined as the reduction in the incidence of a biological material having greater than 5 pg Ca/mg dried material when implanted into a mammalian host organism for about 30 to about 90 days.
[0030] In another exemplary embodiment, calcification is measured by subcutaneously implanting the biological material into a rat for about 90 days.
The bioprosthetic or biological tissue containing calcium above 5 p.g Ca/mg tissue is considered calcified whereas bioprosthetic or biological tissue containing calcium below 5 ~g Ca/mg tissue is considered not calcified. Thus, in this example, mitigation of calcification is defined as the reduction in the incidence of a biological material having greater than 5 ~g Ca/mg material when implanted subcutaneously into a rat for about 90 days.
[0031] In another exemplary embodiment, mitigation of calcification results in elimination of calcification. The term "elimination of calcification" or "eliminating calcification" as used herein, means mitigating calcification wherein no members of a population of implanted biological materials are calcified.
[0032] In another aspect, the present invention provides methods of treating a biological material, wherein the treatment reduces calcium content when the biological material is implanted into a host organism. The methods of treatment to reduce calcium content are also referred to herein as methods of reducing calcium content of a biological tissue. The methods of the present invention reduce calcium content of a biological material relative to methods that are identical with the exception that the SCL step is not performed. Individual steps of the methods of the present invention are described in detail below.
METHODS OF REDUCING PHOSPHOLIPID CONTENT
[0033] In another aspect, the present invention provides methods of treating a biological material, wherein the treatment reduces phospholipid content of the biological material. The methods of treatment to reduce phospholipid content are also referred to herein as methods of reducing phospholipid content of a biological tissue. The methods of the present invention reduce phospholipid content of a biological material relative to methods that are identical with the exception that the SCL step is not performed. Individual steps of the methods of the present invention are described in detail below.
10 [0034] Various methods of reducing phospholipid content in a biological material are useful in the current invention. For example, phospholipid content of a biological material may be measured by extracting the tissue with a solvent mixture to solubilize the phospholipids. Exemplary phospholipids measured include phospholipids present in the tissue due to the cellular nature of the tissue.
[0035] Phospholipid content of a biological material may be correlated to desired or undesired properties resulting from implantation of the biological material. For example, phospholipid content of a biological material may be measured and the biological material may then be implanted into a host organism. The properties of the biological material may then be analyzed. In an exemplary embodiment, phospholipid content is measured and the biological material is subsequently implanted into a mammalian host organism for 30 to 90 days. Surprisingly, in this example, biological material containing phospholipid content below 1 ~g of phospholipids per mg of dried material (hereinafter referred to as pg PL/mg) have superior mechanical properties, enhanced longevity and durability, and increased resistance to failure when used as bioprosthetic tissue compared to biological materials containing more than 1 pg PL/mg. Conversely, biological material containing phospholipid content above 1 ~g PL/mg have inferior mechanical properties, decreased durability, and increased rates of failure when used as bioprosthetic tissue.
[0036] In another exemplary embodiment, phospholipid content is measured and the biological material is subsequently implanted into a rat for about 90 days. In this example, desirable biological material contained less than 1 pg PL/mg and preferably less.
[0037] In another exemplary embodiment, biological material containing less than 0.4 pg PL/mg exhibits desirable properties after implantation into a rat for about 90 days.
[0038] In an exemplary assay, phospholipid content is measured by quantifying selected phospholipids within a sample. A variety of phospholipids may be selected for quantification, including acidic phospholipids, basic phospholipids and neutral phospholipids. In another exemplary embodiment, the selected phospholipids are sphingomyelin, phosphatidylcholine, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, and phosphatidic acid. In another exemplary embodiment, the selected phospholipids include gangliotetraosylceramide (Gg4).
[0039] Thus, in another aspect, the present invention provides methods of treating a biological tissue, wherein the treatment reduces phospholipid content of the biological tissue when implanted into a host organism. The methods of the present invention reduce phospholipids of a biological material relative to methods that are identical with the exception that the SCL step is not performed.
Individual steps of the methods of the present invention are described in detail below.
METHODS OF THE PRESENT INVENTION
[0040] The methods of the present invention provide superior methods for mitigating calcification, reducing calcification, and/or reducing phospholipid levels in an implanted biological material. The methods of the present invention include the step of contacting the biological material with a preparation comprising a surfactant and a cross linking agent without denaturant (hereinafter referred to as the SCL step). In a further embodiment, the methods of the present invention include the step of contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant (hereinafter referred to as the SOLD step).
[0041] In an exemplary embodiment, the methods of the present invention further include, after completion of the SCL and SCLD steps previously discussed, contacting the biological tissue with a terminal liquid sterilization solution.
[0042] In another exemplary embodiment, the methods of the present invention further include, before performing the SCL and SCLD steps, contacting the biological tissue with a fixation solution that comprises a cross linking agent in the absence of denaturant.
[0043] In another aspect, the present invention provides a method of treating a biological material including the steps o~
[0044] (a) first contacting the biological material with a preparation comprising a cross linking agent;
[0045] (b) following (a), contacting the biological material with a preparation comprising a surfactant and a cross linking agent (the SCL step);
[0046] (c) following (b), contacting the biological material with a preparation comprising surfactant, a cross linking agent and a denaturant (the SOLD step);
and [0047] (d) following (c), contacting the biological material with a terminal liquid sterilization solution.
[0048] Exemplary embodiments of these and other steps are discussed in detail below.
Surfactants [0049] Methods of the present invention include contacting a biological material with a surfactant, either alone or in combination with other chemical agents. The treatment can be performed as a single step. Alternatively, the treatment can be performed as a series of sequential steps. At the end of each sequential step, the surfactant is preferably removed and a new fraction of surfactant is added. Surfactants of use in the present invention include any surfactant, either substantially pure or containing additives. An exemplary surfactant is a surface active agent capable of reducing the surface tension of water. Exemplary defining features of surfactants can be found in KIRK-OTHMER'S "ENCYCLOPEDIA OF CHEMICAL TECHNOLOGY," Third Edition, Vol.
22, pp. 332-432, which is hereby incorporated by reference.
[0050] Other exemplary surfactants include anionic, cationic, nonionic, and amphoteric surfactants. In an exemplary embodiment, the method of the present invention uses a nonionic surfactant as the surfactant. Nonionic surfactants include, without limitation, various ethoxylates, carboxylic acid esters, glycol esters, polyoxyethylene esters, anhydrosorbitol esters, ethoxylated anhydrodrosorbitol esters, glycerol esters of fatty acids, carboxylic amides, diethanolamine condensates, and the like. Exemplary nonionic surfactants also include ethoxylated natural fats, oils and waxes. The skilled practitioner will recognize that many other surfactants are suitable for use in the method of the present invention. A list of additional surfactants can be found in U.S.
Patent No. 6,214,054, which is incorporated by reference in its entirety for all purposes.
[0051] The ethoxylated natural fats, oils, and waxes are optionally from a group including, without limitation, lauric, oleic, stearic, and palmitic fatty acids having trade names such as Armotan, Emsorb, Glycosperse, Hodag, and Tween.
5 [0014] Figure 2 illustrates data from experiments to assess 90-day rat subcutaneous pericardial leaflet calcification (pg Ca/mg dry wt) as described in Example 1 below.
[0015] Figure 3 provides data from experiments to assess rat 90-day subcutaneous porcine leaflet calcification (fig Ca/mg dry wt) as described in Example 2 below.
[0016] Figure 4 illustrates data from experiments to assess 90-day rat subcutaneous porcine leaflet calcification (pg Ca/mg dry wt) as described in Example 2 below.
BRIEF SUMMARY OF THE INVENTION
[0017] The present invention provides methods of producing superior biological materials for implantation by mitigating calcification, reducing calcification, and/or reducing phospholipid content in the biological materials upon implantation. The procedures provide biological tissues that are well suited for use in bioprosthetic devices. The invention further provides superior biological materials prepared in accordance with the methods of the invention, and implantable prosthetics that comprise such superior biological materials.
[0018] Thus, in a first aspect, the present invention provides a method of treating a biological material, which comprises contacting the biological material with a preparation that contains a cross linking agent and a surfactant.
The preparation does not contain a denaturant.
[0019] In a second aspect, the present invention provides a method of treating a biological material, which comprises the step of contacting the biological material with a preparation having a surfactant and a cross linking agent in the absence of a denaturant (hereinafter referred to as the SCL step); and the step of contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant (hereinafter referred to as the SCLD
step).
[0020] In a third aspect, the present invention provides a method of treating a biological material that comprises four separate steps performed in a specified sequence. In step one, the biological material is contacted with a preparation containing a cross linking agent in the absence of denaturant and surfactant.
After step one, step two is performed, which comprises contacting the biological material with a preparation containing a cross linking agent and a surfactant in the absence of denaturant. After step two, step three is performed, which comprises contacting the biological material with a preparation containing a cross linking agent, a denaturant and a surfactant. After step three, the biological material is contacted with a terminal liquid sterilization solution.
[0021] In a fourth aspect, the present invention provides a method of treating a biological material that comprises contacting the biological material with a preparation having a cross linking agent and a surfactant in the absence of a denaturant. The method results in mitigation of calcification of the biological material upon implantation into a host organism relative to an identical method of treating the biological material with the exception that the biological material is not contacted with a preparation having a cross linking agent and a surfactant in the absence of a denaturant.
[0022] In a fifth aspect, the present invention provides a method of treating a biological material that comprises contacting the biological material with a preparation having a cross linking agent and a surfactant in the absence of a denaturant. The method results in reduction of phospholipid content of the biological material upon implantation into a host organism relative to an identical method of treating the biological material with the exception that the biological material is not contacted with a preparation having a cross linking agent and a surfactant in the absence of a denaturant.
[0023] In a sixth aspect, the present invention provides a method of treating a biological material that comprises contacting the biological material with a S preparation having a cross linking agent and a surfactant in the absence of a denaturant. The method results in reduction of calcium content of the biological material upon implantation into a host organism relative to an identical method of treating the biological material with the exception that the biological material is not contacted with a preparation having a cross linking agent and a surfactant in the absence of a denaturant.
[0024] In a seventh embodiment, the present invention provides a biological material resistant to calcification produced by a method of treating the biological material comprising the step of contacting the biological material with a preparation comprising a surfactant and a cross linking agent in the absence of a denaturant; and the step of contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant.
[0025] These and other embodiments and advantages of the present invention will be apparent from the detailed description that follows.
DETAILED DESCRIPTION OF THE INVENTION
METHODS OF MITIGATING OR REDUCING CALCIFICATION
[0026] In one aspect, the present invention provides superior methods of treating a biological material, wherein the treatment mitigates calcification when the biological material is implanted into a host organism. The methods of treatment to mitigate calcification are also referred to herein as methods of mitigating calcification of a biological tissue. The methods of the present invention mitigate calcification of a biological material relative to methods that are identical with the exception that the SCL step is not performed.
Individual steps of the methods of the present invention are described in detail below.
[0027] Mitigation of calcification refers to reducing the incidence of calcification. The incidence of calcification refers to the number of members of a population of implanted biological materials for which calcification occurs relative to the total number of members of the population. Elimination of calcification means mitigating calcification wherein no members of a population of implanted biological materials are calcified.
[0028] An exemplary calcification is the accumulation of calcium su~cient to cause stiffening or degradation of biological tissue implanted into a host organism. A variety of techniques are useful in measuring calcification in a biological material after implantation. In an exemplary assay, calcification is measured by implanting the biological material in a host organism for a period of time, removing the implanted biological material, and measuring the calcium levels in the biological material. The biological material may be implanted subcutaneously or intramuscularly in, for example, a mammalian host organism between 10 and 100 days. The mammalian host organism may be any appropriate species, such as a rat or a rabbit.
[0029] Another exemplary calcification is the measurement of calcium accumulation after implantation of the biological material into a mammalian host organism for 30 to 90 days. The biological material is then removed and analyzed for calcium content. Surprisingly, in this example, biological material containing calcium levels below S pg of calcium per mg of dried material (hereinafter referred to as p.g Ca/mg) have superior mechanical properties, enhanced longevity and durability, and increased resistance to failure when used as bioprosthetic tissue compared to biological materials containing more than pg Ca/mg. Conversely, biological material containing calcium levels above 5 pg Ca/mg have inferior mechanical properties, decreased durability, and increased rates of failure when used as bioprosthetic tissue. Therefore, in this example, bioprosthetic or biological tissue containing calcium content above 5 pg Ca/mg tissue is considered calcified whereas bioprosthetic or biological tissue containing calcium content below 5 ~.g Ca/mg tissue is considered not calcified. Thus, in this example, mitigation of calcification is defined as the reduction in the incidence of a biological material having greater than 5 pg Ca/mg dried material when implanted into a mammalian host organism for about 30 to about 90 days.
[0030] In another exemplary embodiment, calcification is measured by subcutaneously implanting the biological material into a rat for about 90 days.
The bioprosthetic or biological tissue containing calcium above 5 p.g Ca/mg tissue is considered calcified whereas bioprosthetic or biological tissue containing calcium below 5 ~g Ca/mg tissue is considered not calcified. Thus, in this example, mitigation of calcification is defined as the reduction in the incidence of a biological material having greater than 5 ~g Ca/mg material when implanted subcutaneously into a rat for about 90 days.
[0031] In another exemplary embodiment, mitigation of calcification results in elimination of calcification. The term "elimination of calcification" or "eliminating calcification" as used herein, means mitigating calcification wherein no members of a population of implanted biological materials are calcified.
[0032] In another aspect, the present invention provides methods of treating a biological material, wherein the treatment reduces calcium content when the biological material is implanted into a host organism. The methods of treatment to reduce calcium content are also referred to herein as methods of reducing calcium content of a biological tissue. The methods of the present invention reduce calcium content of a biological material relative to methods that are identical with the exception that the SCL step is not performed. Individual steps of the methods of the present invention are described in detail below.
METHODS OF REDUCING PHOSPHOLIPID CONTENT
[0033] In another aspect, the present invention provides methods of treating a biological material, wherein the treatment reduces phospholipid content of the biological material. The methods of treatment to reduce phospholipid content are also referred to herein as methods of reducing phospholipid content of a biological tissue. The methods of the present invention reduce phospholipid content of a biological material relative to methods that are identical with the exception that the SCL step is not performed. Individual steps of the methods of the present invention are described in detail below.
10 [0034] Various methods of reducing phospholipid content in a biological material are useful in the current invention. For example, phospholipid content of a biological material may be measured by extracting the tissue with a solvent mixture to solubilize the phospholipids. Exemplary phospholipids measured include phospholipids present in the tissue due to the cellular nature of the tissue.
[0035] Phospholipid content of a biological material may be correlated to desired or undesired properties resulting from implantation of the biological material. For example, phospholipid content of a biological material may be measured and the biological material may then be implanted into a host organism. The properties of the biological material may then be analyzed. In an exemplary embodiment, phospholipid content is measured and the biological material is subsequently implanted into a mammalian host organism for 30 to 90 days. Surprisingly, in this example, biological material containing phospholipid content below 1 ~g of phospholipids per mg of dried material (hereinafter referred to as pg PL/mg) have superior mechanical properties, enhanced longevity and durability, and increased resistance to failure when used as bioprosthetic tissue compared to biological materials containing more than 1 pg PL/mg. Conversely, biological material containing phospholipid content above 1 ~g PL/mg have inferior mechanical properties, decreased durability, and increased rates of failure when used as bioprosthetic tissue.
[0036] In another exemplary embodiment, phospholipid content is measured and the biological material is subsequently implanted into a rat for about 90 days. In this example, desirable biological material contained less than 1 pg PL/mg and preferably less.
[0037] In another exemplary embodiment, biological material containing less than 0.4 pg PL/mg exhibits desirable properties after implantation into a rat for about 90 days.
[0038] In an exemplary assay, phospholipid content is measured by quantifying selected phospholipids within a sample. A variety of phospholipids may be selected for quantification, including acidic phospholipids, basic phospholipids and neutral phospholipids. In another exemplary embodiment, the selected phospholipids are sphingomyelin, phosphatidylcholine, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, and phosphatidic acid. In another exemplary embodiment, the selected phospholipids include gangliotetraosylceramide (Gg4).
[0039] Thus, in another aspect, the present invention provides methods of treating a biological tissue, wherein the treatment reduces phospholipid content of the biological tissue when implanted into a host organism. The methods of the present invention reduce phospholipids of a biological material relative to methods that are identical with the exception that the SCL step is not performed.
Individual steps of the methods of the present invention are described in detail below.
METHODS OF THE PRESENT INVENTION
[0040] The methods of the present invention provide superior methods for mitigating calcification, reducing calcification, and/or reducing phospholipid levels in an implanted biological material. The methods of the present invention include the step of contacting the biological material with a preparation comprising a surfactant and a cross linking agent without denaturant (hereinafter referred to as the SCL step). In a further embodiment, the methods of the present invention include the step of contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant (hereinafter referred to as the SOLD step).
[0041] In an exemplary embodiment, the methods of the present invention further include, after completion of the SCL and SCLD steps previously discussed, contacting the biological tissue with a terminal liquid sterilization solution.
[0042] In another exemplary embodiment, the methods of the present invention further include, before performing the SCL and SCLD steps, contacting the biological tissue with a fixation solution that comprises a cross linking agent in the absence of denaturant.
[0043] In another aspect, the present invention provides a method of treating a biological material including the steps o~
[0044] (a) first contacting the biological material with a preparation comprising a cross linking agent;
[0045] (b) following (a), contacting the biological material with a preparation comprising a surfactant and a cross linking agent (the SCL step);
[0046] (c) following (b), contacting the biological material with a preparation comprising surfactant, a cross linking agent and a denaturant (the SOLD step);
and [0047] (d) following (c), contacting the biological material with a terminal liquid sterilization solution.
[0048] Exemplary embodiments of these and other steps are discussed in detail below.
Surfactants [0049] Methods of the present invention include contacting a biological material with a surfactant, either alone or in combination with other chemical agents. The treatment can be performed as a single step. Alternatively, the treatment can be performed as a series of sequential steps. At the end of each sequential step, the surfactant is preferably removed and a new fraction of surfactant is added. Surfactants of use in the present invention include any surfactant, either substantially pure or containing additives. An exemplary surfactant is a surface active agent capable of reducing the surface tension of water. Exemplary defining features of surfactants can be found in KIRK-OTHMER'S "ENCYCLOPEDIA OF CHEMICAL TECHNOLOGY," Third Edition, Vol.
22, pp. 332-432, which is hereby incorporated by reference.
[0050] Other exemplary surfactants include anionic, cationic, nonionic, and amphoteric surfactants. In an exemplary embodiment, the method of the present invention uses a nonionic surfactant as the surfactant. Nonionic surfactants include, without limitation, various ethoxylates, carboxylic acid esters, glycol esters, polyoxyethylene esters, anhydrosorbitol esters, ethoxylated anhydrodrosorbitol esters, glycerol esters of fatty acids, carboxylic amides, diethanolamine condensates, and the like. Exemplary nonionic surfactants also include ethoxylated natural fats, oils and waxes. The skilled practitioner will recognize that many other surfactants are suitable for use in the method of the present invention. A list of additional surfactants can be found in U.S.
Patent No. 6,214,054, which is incorporated by reference in its entirety for all purposes.
[0051] The ethoxylated natural fats, oils, and waxes are optionally from a group including, without limitation, lauric, oleic, stearic, and palmitic fatty acids having trade names such as Armotan, Emsorb, Glycosperse, Hodag, and Tween.
[0052] In another exemplary embodiment, the surfactant is polyoxyethylene sorbitan monooleate (Tween 80). Surfactants such as Tween 80 are widely used in biochemical applications including: solubilizing proteins, isolating nuclei from cells in culture, growing of tubercule bacilli, and emulsifying and dispersing substances in medicinal and food products.
[0053] In an exemplary embodiment, the tissue is treated with a preparation or solution containing from about 0.1 % to about 50% surfactant by weight. In another exemplary embodiment, the tissue is treated with a preparation or solution containing from about 0.1% to about 10% surfactant. In another exemplary embodiment, the tissue is treated with a preparation or solution containing more than 0.6% and less than 50% surfactant. In another exemplary embodiment, the preparation or solution contains from about 1.7% to about 25 surfactant. In another exemplary embodiment, the preparation or solution contains 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, or 2.9%
surfactant. In another exemplary embodiment, the preparation or solution contains 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% surfactant.
Cross Linking-Agents [0054] Methods of the present invention include contacting a biological material with a cross linking agent, either alone or in combination with other chemical agents. The treatment can be performed as a single step.
Alternatively, the treatment can be performed as a series of sequential steps.
At the end of each sequential step, the cross linking agent is preferably removed and a new fraction of cross linking agent is added. Exemplary cross linking agents include compounds capable of stabilizing the structure of a biological material through the formation of covalent bonds.
[0055] Exemplary cross-linking reagents include, but are not limited to, aldehydes (e.g., formaldehyde, glutaraldehyde, dialdehyde starch, para formaldehyde, glyceraldehyde, glyoxal acetaldehyde, acrolein), diisocyanates (e.g., hexamethylene diisocyanate), carbodiimides (e.g.
dicyclohexylcarbodiimide, 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride), polyepoxy compounds (e.g., Denacol-810, -512), bifunctional 5 maleimide compounds (e.g. 1,4-Bis-maleimidtyl-2,3-dihydroxybutane, N-((3-maleimidopropyloxy) sucinimide ester), bifunctional N-hydroxysuccinimide ester compounds (e.g. disuccinimidyl glutarate, 3,3'-dithiobis(sulfosuccinimidyl propionate)), bifunctional imidoester compounds (e.g. dimethyl suberimidate), bifunctional pyridylthio compounds (e.g. 1,4-di-[3'-(2'-pyridylthio)-10 propionamido]butane), bifunctional vinylsulfone compounds (e.g. 1, 6-hexane-bis-vinylsulfone) and photoactivatable cross-linkers (e.g. azides, phenyl azides).
[0056] In an exemplary embodiment, the cross linking agent is an aldehyde, including both mono- and poly-aldehydes. Aldehydes of use in practicing the present invention include any aldehyde, either substantially pure or containing 15 additives. Exemplary aldehydes include one or more compounds of the following: acetaldehyde, butyraldehyde, isobutyraldehyde, propionaldehyde, a-methylpropionaldehyde, 2-methylbutyraldehyde, cyclopentanecarbaldehyde, benzaldehyde, caproaldehyde, carbaldehyde, glutaraldehyde, formaldehyde and the like.
[0057] One skilled in the art will recognize that different cross linking agents may be used at different steps of the present method. Determining acceptable cross linking agents to be used at each step of the present method is well within the abilities of those of skill in the art given the guidance of the teachings herein.
[0058] In an exemplary embodiment, the tissue is treated with substantially any amount of aldehyde that provides the sought after results. The determination of the correct amount of aldehyde needed for a particular application is well within the abilities of those of skill in the art. For example, a biological tissue is contacted one or more times with aldehyde and the biological material is collected and analyzed.
[0059] In an exemplary embodiment, the cross linking agent is formaldehyde.
A variety of formaldehyde concentrations are useful in the present invention.
In S an exemplary embodiment, the tissue is treated with a formaldehyde solution containing from about 0.1% to about 50% formaldehyde by weight. In another exemplary embodiment, the tissue is treated with a formaldehyde solution containing from about 1 % to about 10% formaldehyde. In another exemplary embodiment, the tissue is treated with a formaldehyde solution containing about 4% formaldehyde.
[0060] In another exemplary embodiment, the cross linking agent is glutaraldehyde. A variety of glutaraldehyde concentrations are useful in the present invention. In an exemplary embodiment, the tissue is treated with a solution of glutaraldehyde containing from about 0.1 % to about 50% of glutaraldehyde. In another exemplary embodiment, the tissue is treated with a solution of glutaraldehyde containing from about 0.2% to about 3% of glutaraldehyde.
[0061] Although certain preferred embodiments of the present invention are illustrated by the use of formaldehyde or glutaraldehyde to mitigate calcification from mammalian tissue, the focus on the use of these two aldehydes is for clarity of illustration and should not be construed as defining or limiting the scope of the invention.
[0062] The skilled practitioner will recognize that other agents are suitable for use in the method of the present invention. An exemplary agent of use in the invention is a cross linking agent. A list of cross linking agents can be found in U.S. Patent No. 6,214,054, which is incorporated herein by reference in its entirety.
[0053] In an exemplary embodiment, the tissue is treated with a preparation or solution containing from about 0.1 % to about 50% surfactant by weight. In another exemplary embodiment, the tissue is treated with a preparation or solution containing from about 0.1% to about 10% surfactant. In another exemplary embodiment, the tissue is treated with a preparation or solution containing more than 0.6% and less than 50% surfactant. In another exemplary embodiment, the preparation or solution contains from about 1.7% to about 25 surfactant. In another exemplary embodiment, the preparation or solution contains 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, or 2.9%
surfactant. In another exemplary embodiment, the preparation or solution contains 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% surfactant.
Cross Linking-Agents [0054] Methods of the present invention include contacting a biological material with a cross linking agent, either alone or in combination with other chemical agents. The treatment can be performed as a single step.
Alternatively, the treatment can be performed as a series of sequential steps.
At the end of each sequential step, the cross linking agent is preferably removed and a new fraction of cross linking agent is added. Exemplary cross linking agents include compounds capable of stabilizing the structure of a biological material through the formation of covalent bonds.
[0055] Exemplary cross-linking reagents include, but are not limited to, aldehydes (e.g., formaldehyde, glutaraldehyde, dialdehyde starch, para formaldehyde, glyceraldehyde, glyoxal acetaldehyde, acrolein), diisocyanates (e.g., hexamethylene diisocyanate), carbodiimides (e.g.
dicyclohexylcarbodiimide, 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride), polyepoxy compounds (e.g., Denacol-810, -512), bifunctional 5 maleimide compounds (e.g. 1,4-Bis-maleimidtyl-2,3-dihydroxybutane, N-((3-maleimidopropyloxy) sucinimide ester), bifunctional N-hydroxysuccinimide ester compounds (e.g. disuccinimidyl glutarate, 3,3'-dithiobis(sulfosuccinimidyl propionate)), bifunctional imidoester compounds (e.g. dimethyl suberimidate), bifunctional pyridylthio compounds (e.g. 1,4-di-[3'-(2'-pyridylthio)-10 propionamido]butane), bifunctional vinylsulfone compounds (e.g. 1, 6-hexane-bis-vinylsulfone) and photoactivatable cross-linkers (e.g. azides, phenyl azides).
[0056] In an exemplary embodiment, the cross linking agent is an aldehyde, including both mono- and poly-aldehydes. Aldehydes of use in practicing the present invention include any aldehyde, either substantially pure or containing 15 additives. Exemplary aldehydes include one or more compounds of the following: acetaldehyde, butyraldehyde, isobutyraldehyde, propionaldehyde, a-methylpropionaldehyde, 2-methylbutyraldehyde, cyclopentanecarbaldehyde, benzaldehyde, caproaldehyde, carbaldehyde, glutaraldehyde, formaldehyde and the like.
[0057] One skilled in the art will recognize that different cross linking agents may be used at different steps of the present method. Determining acceptable cross linking agents to be used at each step of the present method is well within the abilities of those of skill in the art given the guidance of the teachings herein.
[0058] In an exemplary embodiment, the tissue is treated with substantially any amount of aldehyde that provides the sought after results. The determination of the correct amount of aldehyde needed for a particular application is well within the abilities of those of skill in the art. For example, a biological tissue is contacted one or more times with aldehyde and the biological material is collected and analyzed.
[0059] In an exemplary embodiment, the cross linking agent is formaldehyde.
A variety of formaldehyde concentrations are useful in the present invention.
In S an exemplary embodiment, the tissue is treated with a formaldehyde solution containing from about 0.1% to about 50% formaldehyde by weight. In another exemplary embodiment, the tissue is treated with a formaldehyde solution containing from about 1 % to about 10% formaldehyde. In another exemplary embodiment, the tissue is treated with a formaldehyde solution containing about 4% formaldehyde.
[0060] In another exemplary embodiment, the cross linking agent is glutaraldehyde. A variety of glutaraldehyde concentrations are useful in the present invention. In an exemplary embodiment, the tissue is treated with a solution of glutaraldehyde containing from about 0.1 % to about 50% of glutaraldehyde. In another exemplary embodiment, the tissue is treated with a solution of glutaraldehyde containing from about 0.2% to about 3% of glutaraldehyde.
[0061] Although certain preferred embodiments of the present invention are illustrated by the use of formaldehyde or glutaraldehyde to mitigate calcification from mammalian tissue, the focus on the use of these two aldehydes is for clarity of illustration and should not be construed as defining or limiting the scope of the invention.
[0062] The skilled practitioner will recognize that other agents are suitable for use in the method of the present invention. An exemplary agent of use in the invention is a cross linking agent. A list of cross linking agents can be found in U.S. Patent No. 6,214,054, which is incorporated herein by reference in its entirety.
Biological Material [0063] Exemplary biological materials include those at least partially composed of a material of biological origin. Examples of biological materials from a human or an animal include, without limitation, tissue such as brain, muscle (including heart), liver, appendix, pancreas, gastrointestinal tract organs, skin, bone, cartilage, tendon, ligament, connective tissue, and lymphoid tissue such as thymus, spleen, tonsil, lymph nodes, and the like. Alternatively, the biological material may be a biological fluid. The term biological fluid includes, without limitation, to cerebrospinal fluid, blood, serum, plasma, milk, urine, saliva, tears, mucous secretions, sweat, semen and bodily fluids comprising these components. Biological materials may also include culture fluid (or culture medium) used in the production of recombinant proteins or containing cells in suspension prior to transplantation. In another exemplary embodiment, biological materials include products made from human or animal organs or tissues, including serum proteins (such as albumin and immunoglobulin), hormones, food and processed food products, nutritional supplements, bone meal, animal feed, extracellular matrix proteins, gelatin, and other human or animal by products used in manufacturing or final goods.
Biological materials may also refer to any material that can be found in a human or animal that is susceptible to infection or that may carry or transmit infection.
[0064] In another exemplary embodiment, the biological material is a bioprosthetic tissue. The bioprosthetic tissue may be incorporated into a bioprosthesis structure for implantation in the body. Bioprosthetic tissue may be comprised entirely of material of biological origin or may additionally comprise material of non-biological origin. One skilled in the art will readily recognize that various methods of assembling a bioprosthesis may be used to incorporate the bioprosthetic tissue into the bioprosthesis. In a further preferred embodiment, the bioprosthetic tissue is a biological tissue.
Biological materials may also refer to any material that can be found in a human or animal that is susceptible to infection or that may carry or transmit infection.
[0064] In another exemplary embodiment, the biological material is a bioprosthetic tissue. The bioprosthetic tissue may be incorporated into a bioprosthesis structure for implantation in the body. Bioprosthetic tissue may be comprised entirely of material of biological origin or may additionally comprise material of non-biological origin. One skilled in the art will readily recognize that various methods of assembling a bioprosthesis may be used to incorporate the bioprosthetic tissue into the bioprosthesis. In a further preferred embodiment, the bioprosthetic tissue is a biological tissue.
[0065] Biological tissues may be selected from a variety of tissue types, including substantially any mammalian tissue that is useful in preparing a bioprosthesis having a biological component thereto. For example, in one embodiment, the biological tissue is derived from an organ. In another embodiment, the biological tissue is selected from nerve tissue, glandular tissue (e.g., lymphatic tissue), respiratory tissue, digestive tissue, urinary tract tissue, sensory tissue (e.g., cornea, lens, etc.), and reproductive tissue. In a related embodiment where the biological tissue is a biological fluid, however, addition of liquid is not likely to be necessary, unless to dilute the ionic strength of the biological fluid to permit miscibility of the extraction solvent.
[0066] In an exemplary embodiment, the biological tissue is selected from muscle tissue, adipose tissue, epithelial tissue and endothelial tissue. In another exemplary embodiment, the biological tissue is selected from myocardial tissue and vascular tissue. In a related embodiment, the biological tissue is selected from the group including, without limitation, heart valve, venous valve, blood vessel, aorta, artery, ureter, tendon, dura mater, skin, pericardium, intestine (e.g., intestinal wall),or periosteum. In another exemplary embodiment, the biological tissue is derived from bone, cartilage (e.g. meniscus), tendon, ligament, or any other connective tissue. In another exemplary embodiment, the biological tissue is porcine aortic tissue or bovine pericardium tissue.
[0067] As the source of the biological material used for this purpose may vary with regard to tissue type, the source may also vary with regard to species type (autologous, homologous or heterologous tissue). The artisan will appreciate that the methods of the present invention may be used with bioprosthetic devices that include one or more types of tissues or materials.
[0068] In an exemplary embodiment where the biological material is a solid tissue or product, it may first be suspended in an aqueous solution so that it will be suitable for use in the methods of the present invention. For example, brain tissue may be suspended in sucrose solution (e.g., 0.32 M sucrose) at 10%
[0066] In an exemplary embodiment, the biological tissue is selected from muscle tissue, adipose tissue, epithelial tissue and endothelial tissue. In another exemplary embodiment, the biological tissue is selected from myocardial tissue and vascular tissue. In a related embodiment, the biological tissue is selected from the group including, without limitation, heart valve, venous valve, blood vessel, aorta, artery, ureter, tendon, dura mater, skin, pericardium, intestine (e.g., intestinal wall),or periosteum. In another exemplary embodiment, the biological tissue is derived from bone, cartilage (e.g. meniscus), tendon, ligament, or any other connective tissue. In another exemplary embodiment, the biological tissue is porcine aortic tissue or bovine pericardium tissue.
[0067] As the source of the biological material used for this purpose may vary with regard to tissue type, the source may also vary with regard to species type (autologous, homologous or heterologous tissue). The artisan will appreciate that the methods of the present invention may be used with bioprosthetic devices that include one or more types of tissues or materials.
[0068] In an exemplary embodiment where the biological material is a solid tissue or product, it may first be suspended in an aqueous solution so that it will be suitable for use in the methods of the present invention. For example, brain tissue may be suspended in sucrose solution (e.g., 0.32 M sucrose) at 10%
weight to volume. Other hypotonic or isotonic solutions include S% dextrose, phosphate buffered saline, tri-buffered saline, HEPES-buffered saline, or any of the foregoing buffers. The biological material in the aqueous solution can also be homogenized, ground, or otherwise disrupted to maximize contact between the treatment agents and the biological material.
[0069] In another exemplary embodiment, cross linking agents are used to maintain the structural integrity of the biological tissue. Structural integrity can be defined as the ability of tissue to perform its necessary biological function.
The artisan will appreciate that the degree of structural integrity required for the tissue to perform its necessary function may vary among different types of tissues. Further, particular applications for which the tissue is used may require different levels of structural integrity.
The SCL Sten [0070] The methods of the present invention include the step of contacting the biological material with a preparation comprising a surfactant and a cross linking agent without denaturant (hereinafter referred to as the SCL
preparation). Biological materials, cross linking agents, and surfactants useful in the current invention are discussed above and are likewise useful here in the SCL preparation.
[0071] In an exemplary embodiment more than one SCL step is performed.
In another exemplary embodiment, the SCL step is performed from 1 to 5 times.
In another exemplary embodiment, the biological material is contacted with the SCL preparation only once.
[0072] A variety of surfactant concentrations are useful in the SCL
preparation. In an exemplary embodiment, the tissue is treated with a SCL
preparation containing from about 0.1% to about 50% surfactant by weight. In another exemplary embodiment, the tissue is treated with a SCL preparation containing from about 0.1 % to about 10% surfactant. In another exemplary embodiment, the tissue is treated with a SCL preparation containing more than 0.6% and less than 50% surfactant. In another exemplary embodiment, the SCL
preparation contains from about 1.7% to about 25 % surfactant. In another exemplary embodiment, the SCL preparation contains 0.7%, 0.8%, 0.9%, 1.0%, 5 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6, 2.7, 2.8, or 2.9% surfactant. In another exemplary embodiment, the SCL preparation contains 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% surfactant.
[0073] As discussed above, a variety of surfactants are useful in the methods 10 of the present invention, including the SCL preparation. In an exemplary embodiment, the surfactant used in the SCL preparation is a nonionic surfactant.
In another exemplary embodiment, the nonionic surfactant is Tween 80. In another exemplary embodiment, the SCL preparation contains 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 15 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, or 2.9% of Tween 80. In another exemplary embodiment, the SCL preparation contains 3%, 4%, S%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% of Tween 80.
[0074] One skilled in the art will recognize that different surfactants may be 20 used in the SCL step of the present method. Determining acceptable surfactants and surfactant levels to be used is well within the abilities of those of skill in the art given the guidance of the teachings herein.
[0075] In an exemplary embodiment, the biological tissue is treated with a SCL preparation containing a aldehyde as the cross linking agent. In a related embodiment, the aldehyde is glutaraldehyde. A variety of glutaraldehyde concentrations may be used in the SCL preparation. In an exemplary embodiment, the preparation contains from about 0.1% to about SO%
glutaraldehyde by weight. In another exemplary embodiment, the tissue is treated with a SCL preparation containing from about 0.2% to about 3% of glutaraldehyde.
[0076] Typically, the SCL step is performed at any appropriate temperature selected to provide optimal calcification reduction, calcification mitigation, and/or phospholipid content reduction. In exemplary embodiment, the SCL step is performed at approximately a single temperature. In another exemplary embodiment, the SCL step is performed at more than one temperature.
[0077] In another exemplary embodiment, the SCL step is performed at approximately room temperature. In another exemplary embodiment, heat is applied to the SCL preparation. In another exemplary embodiment, the SCL
step is performed at a temperature between about 25°C and 55°C.
In another exemplary embodiment, the SCL step is performed between about 35°C and 55°C. In another exemplary embodiment, the SCL step is performed between about 35°C and 45°C. In another exemplary embodiment, the SCL
step is performed between about 35°C and 40°C. In another exemplary embodiment, the SCL step is performed at a temperature of about 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, or 45°C.
[0078] Typically, the SCL step is performed for a time selected to provide optimal calcification mitigation, calcification reduction or phospholipid content reduction. In an exemplary embodiment, the biological material is contacted with the SCL preparation for about 1 day to about 20 days. In another exemplary embodiment, the SCL step lasts from 5 days to about 15 days.
[0079] In another exemplary embodiment, the SCL step is at least about 12 days. In another exemplary embodiment, the SCL step is at least about 12 days and the SCL preparation comprises at least about 1.7% surfactant.
[0080] In another exemplary embodiment, the SCL step is performed at a pH
selected to provide optimal calcification mitigation or phospholipid content reduction. In an exemplary embodiment, the pH of the SCL solution is between about 6 and about 8. In another exemplary embodiment, the pH is maintained at about 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, or 7.9.
[0081] The SCL step can be performed as a single step. Alternatively, the SCL step can be performed as a series of sequential steps. At the end of each sequential step, the SCL preparation is preferably removed from the tissue prior to contacting the tissue with a new fraction of SCL preparation.
The SCLD Step [0082] The methods of the present invention include the step of contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant (hereinafter referred to as the SCLD preparation).
Biological materials, cross linking agents, and surfactants useful in the current invention are discussed above and are likewise useful here in the SCLD
preparation.
[0083] The SCLD step may be performed at different stages in the methods of the current invention. In an exemplary embodiment, the SCLD step is performed after the SCL step. In another exemplary embodiment, the SCLD
step is performed before the SCL step.
[0084] The SCLD step may also be referred to as a bioburden reduction step.
In an exemplary embodiment, more than one SCLD step is performed. In another exemplary embodiment, two SOLD steps are performed. In an exemplary embodiment where two SCLD steps are performed, the first SCLD
step may be referred to as an initial bioburden reduction step (iBReP) and the second SCLD step may be referred to as a final bioburden reduction step (fBReP).
[0085] A variety of denaturants are useful in the SCLD step of the present invention. In an exemplary embodiment, the denaturant produces a reversible or irreversible loss of higher order structure other than the primary structure of proteins in a biological material. In another exemplary embodiment, the denaturant is a protic solvent useful in removing infectious materials or chemical agents. Protic solvents of use in practicing the present invention include water, alcohols, carboxylic acids, and the like. In another exemplary embodiment, the denaturant is an alcohol or other solvent incorporating an alcohol. The biological material is treated with substantially any amount of alcohol that provides the sought after results.
[0086] The determination of the correct amount of alcohol needed for a particular application is well within the abilities of those of skill in the art. For example, a biological tissue is subjected to one or more SCLD steps and the biological material is collected. The amount of infectious material or chemical agent removed by the SCLD step is determined. When the alcohol ceases to remove infectious agent or chemical agent from the tissue an end point is reached, which is indicative of the amount of alcohol necessary to remove the particular agent from the tissue. In an exemplary embodiment utilizing an alcohol, the tissue is treated with an aqueous alcohol solution containing from about 1% to about 100% alcohol, more preferably from about 10% to about 80% alcohol.
[0087] Exemplary alcohols include one or more compounds of the group consisting of methanol, ethyl alcohol, propyl alcohol, butyl alcohol, pentyl alcohol, hexyl alcohol, heptyl alcohol, octyl alcohol, nonyl alcohol, decyl alcohol, long chain alcohols (e.g. 1,2-octanediol) and the like. In another exemplary embodiment, a method of the present invention uses ethanol. In another exemplary embodiment, the alcohol is isopropyl alcohol.
[0088] As discussed above, a variety of cross linking agents are useful in the methods of the present invention, including the SCLD preparation. In an exemplary embodiment, the SCLD preparation comprises an aldehyde as the cross linking agent. In a further exemplary embodiment, formaldehyde is the cross linking agent. A variety of formaldehyde concentrations are useful in the SCLD preparation. In an exemplary embodiment, the SCLD preparation comprises about 0.5% to about 10% formaldehyde. In another exemplary embodiment, the SCLD preparation comprises about 4% formaldehyde.
(0089] The SCLD preparation may employ any appropriate surfactant. In an exemplary embodiment, the surfactant used in the SCLD preparation is a nonionic surfactant. In another exemplary embodiment, the SCLD preparation comprises Tween 80 as the surfactant. In another exemplary embodiment, the SCLD preparation comprises about 0.5% to about 5% Tween 80. In another exemplary embodiment, the SCLD preparation comprises about 2.1 % of Tween 80.
[0090] In an exemplary embodiment, the SCLD step is performed at a temperature selected to provide optimal calcification mitigation, calcification reduction and/or reduction of phospholipid content of a biological material.
In exemplary embodiment, the SCLD step is performed at approximately a single temperature. In another exemplary embodiment, the SCLD step is performed at more than one temperature.
[0091] In another exemplary embodiment, the SCLD step is performed at approximately room temperature. In another exemplary embodiment, heat is applied to the SCLD preparation. In another exemplary embodiment, the SCLD
step is performed at a temperature between about 30°C and 55°C.
In another exemplary embodiment, the SCLD step is performed between about 30°C and about40°C.
[0092] In another exemplary embodiment, two SCLD steps are preformed: an iBReP step and an fBReP step. In another exemplary embodiment, the iBReP
step is performed at about room temperature and the fBReP step is performed at a temperature above room temperature. In another exemplary embodiment, the fBReP step is performed between about 30°C and about 37°C.
[0093] In another exemplary embodiment, each SCLD step is performed for a time selected to provide optimal calcification mitigation, calcification reduction and/or reduction of phospholipid content of a biological material. In another exemplary embodiment, the iBReP step is performed from about 1 hour to about 4 hours and the fBReP step is performed from about 5 hours to about 15 hours.
5 [0094] In another exemplary embodiment, the SCLD step is performed at a pH selected to provide optimal calcification mitigation, calcification reduction and/or reduction of phospholipid content of a biological material. In another exemplary embodiment, the pH of the SCLD solution is between about 6 and about 8. In another exemplary embodiment, the pH is maintained at about 7.0, 10 7.1,7.2,7.3,7.4,7.5,7.6,7.7,7.8,or7.9.
[0095] The SCLD step can be performed as a single step. Alternatively, the extraction can be performed as a series of sequential steps. At the end of each sequential step, the SCLD preparation is preferably removed prior to contacting the tissue with a new fraction of the SCLD preparation.
15 [0096] In an exemplary embodiment, the SCLD step is performed before the SCL step. In another exemplary embodiment, the SOLD step is performed after the SCL step.
Contacting a Biological Material with a Terminal Liquid Sterilization Solution [0097] In an exemplary embodiment, the methods of the present invention 20 further include contacting the biological tissue with a terminal liquid sterilization solution. Typically, the biological tissue is contacted with a terminal liquid sterilization solution after completion of the SCL and SCLD
steps previously discussed.
[0098] Exemplary terminal liquid sterilization solutions (hereinafter referred 25 to as "TLS" solutions) are capable of sterilizing the biological material before implantation. Sterilants useful in the current invention include cross linking agents, heat, radiation, electron beams, ultraviolet radiation, and combinations thereof. In an exemplary embodiment, the TLS solution comprises heat and a cross linking reagent. Exemplary cross linking agents useful in the TLS
solution are described above.
[0099] In an exemplary embodiment, the TLS solution is heated to a temperature from about 35°C to about 50°C. In another exemplary embodiment, TLS solution is heated to a temperature from about 35°C to about 40°C.
[0100] In another exemplary embodiment, the TLS solution is maintained at a pH between about 6 and 9. In another exemplary embodiment, the TLS
solution is maintained at a pH between about 7.2-7.5.
[0101] In an exemplary embodiment, the TLS solution is contacted with the biological material for sufficient time to sterilize the biological material.
One of skill will recognize that the time required for sterilization will depend on the stringency of the TLS solution. For example, a TLS solution containing an aldehyde that is heated to about 37°C may require 1 to 6 days to sterilize the biological material whereas heating the TLS solution to 50°C may decrease the required time to 25 hours.
[0102] In another exemplary embodiment, the TLS solution comprises about 0.2% to about 2.0% by weight glutaraldehyde.
[0103] In another exemplary embodiment, the terminal sterilization time and temperature is 1-6 days at 37 degrees Celsius. In another particularly preferred embodiment, the terminal sterilization time and temperature is 1-2 days at 50 degrees Celsius. One skilled in the art will recognize that other terminal sterilization times and temperatures may be adjusted while maintaining the effectiveness of the TLS solution.
Contacting a Biological Material with a Cross Linking-A e~nt [0104] In an exemplary embodiment, the methods of the present invention further include contacting the biological tissue with a fixation solution that comprises a cross linking agent in the absence of denaturant. The biological tissue is contacted with the fixation solution before the SCL and SCLD steps, after the SCL and SCLD steps, or between the SCL and SCLD steps. Typically, the biological tissue is contacted with the fixation solution before the SCL
and SCLD steps.
[0105] Fixation solutions useful in the present invention include a cross linking agent to effect crosslinking of the connective tissue proteins within the tissue. Cross linking agents useful in the current invention are discussed above and are likewise useful here in the fixation solution.
[0106] In an exemplary embodiment, the fixation solution contains a cross linking agent at a concentration of about 0.2% to about 2.0 % by weight. In another exemplary embodiment, the cross linking reagent is glutaraldehyde. In another exemplary embodiment, the fixation solution contains glutaraldehyde as the cross linking agent at a concentration of about 0.2% to about 2.0 % by weight.
[0107] In another exemplary embodiment, the fixation solution is contacted with the biological material from about 0.5 hours to about 14 days. In another exemplary embodiment, the fixation solution is contacted with the biological material for about 1-4 days. In another exemplary embodiment, the fixation solution is contacted with the biological material for about 2 days.
[0108] In another exemplary embodiment, the fixation solution further comprises a surfactant. Useful surfactants and surfactant concentrations are described above and are equally applicable to the fixation solution.
[0109] The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding equivalents of the features shown and described, or portions thereof, it being recognized that various modifications are possible within the scope of the invention claimed.
[0069] In another exemplary embodiment, cross linking agents are used to maintain the structural integrity of the biological tissue. Structural integrity can be defined as the ability of tissue to perform its necessary biological function.
The artisan will appreciate that the degree of structural integrity required for the tissue to perform its necessary function may vary among different types of tissues. Further, particular applications for which the tissue is used may require different levels of structural integrity.
The SCL Sten [0070] The methods of the present invention include the step of contacting the biological material with a preparation comprising a surfactant and a cross linking agent without denaturant (hereinafter referred to as the SCL
preparation). Biological materials, cross linking agents, and surfactants useful in the current invention are discussed above and are likewise useful here in the SCL preparation.
[0071] In an exemplary embodiment more than one SCL step is performed.
In another exemplary embodiment, the SCL step is performed from 1 to 5 times.
In another exemplary embodiment, the biological material is contacted with the SCL preparation only once.
[0072] A variety of surfactant concentrations are useful in the SCL
preparation. In an exemplary embodiment, the tissue is treated with a SCL
preparation containing from about 0.1% to about 50% surfactant by weight. In another exemplary embodiment, the tissue is treated with a SCL preparation containing from about 0.1 % to about 10% surfactant. In another exemplary embodiment, the tissue is treated with a SCL preparation containing more than 0.6% and less than 50% surfactant. In another exemplary embodiment, the SCL
preparation contains from about 1.7% to about 25 % surfactant. In another exemplary embodiment, the SCL preparation contains 0.7%, 0.8%, 0.9%, 1.0%, 5 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6, 2.7, 2.8, or 2.9% surfactant. In another exemplary embodiment, the SCL preparation contains 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% surfactant.
[0073] As discussed above, a variety of surfactants are useful in the methods 10 of the present invention, including the SCL preparation. In an exemplary embodiment, the surfactant used in the SCL preparation is a nonionic surfactant.
In another exemplary embodiment, the nonionic surfactant is Tween 80. In another exemplary embodiment, the SCL preparation contains 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 15 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, or 2.9% of Tween 80. In another exemplary embodiment, the SCL preparation contains 3%, 4%, S%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% of Tween 80.
[0074] One skilled in the art will recognize that different surfactants may be 20 used in the SCL step of the present method. Determining acceptable surfactants and surfactant levels to be used is well within the abilities of those of skill in the art given the guidance of the teachings herein.
[0075] In an exemplary embodiment, the biological tissue is treated with a SCL preparation containing a aldehyde as the cross linking agent. In a related embodiment, the aldehyde is glutaraldehyde. A variety of glutaraldehyde concentrations may be used in the SCL preparation. In an exemplary embodiment, the preparation contains from about 0.1% to about SO%
glutaraldehyde by weight. In another exemplary embodiment, the tissue is treated with a SCL preparation containing from about 0.2% to about 3% of glutaraldehyde.
[0076] Typically, the SCL step is performed at any appropriate temperature selected to provide optimal calcification reduction, calcification mitigation, and/or phospholipid content reduction. In exemplary embodiment, the SCL step is performed at approximately a single temperature. In another exemplary embodiment, the SCL step is performed at more than one temperature.
[0077] In another exemplary embodiment, the SCL step is performed at approximately room temperature. In another exemplary embodiment, heat is applied to the SCL preparation. In another exemplary embodiment, the SCL
step is performed at a temperature between about 25°C and 55°C.
In another exemplary embodiment, the SCL step is performed between about 35°C and 55°C. In another exemplary embodiment, the SCL step is performed between about 35°C and 45°C. In another exemplary embodiment, the SCL
step is performed between about 35°C and 40°C. In another exemplary embodiment, the SCL step is performed at a temperature of about 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, or 45°C.
[0078] Typically, the SCL step is performed for a time selected to provide optimal calcification mitigation, calcification reduction or phospholipid content reduction. In an exemplary embodiment, the biological material is contacted with the SCL preparation for about 1 day to about 20 days. In another exemplary embodiment, the SCL step lasts from 5 days to about 15 days.
[0079] In another exemplary embodiment, the SCL step is at least about 12 days. In another exemplary embodiment, the SCL step is at least about 12 days and the SCL preparation comprises at least about 1.7% surfactant.
[0080] In another exemplary embodiment, the SCL step is performed at a pH
selected to provide optimal calcification mitigation or phospholipid content reduction. In an exemplary embodiment, the pH of the SCL solution is between about 6 and about 8. In another exemplary embodiment, the pH is maintained at about 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, or 7.9.
[0081] The SCL step can be performed as a single step. Alternatively, the SCL step can be performed as a series of sequential steps. At the end of each sequential step, the SCL preparation is preferably removed from the tissue prior to contacting the tissue with a new fraction of SCL preparation.
The SCLD Step [0082] The methods of the present invention include the step of contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant (hereinafter referred to as the SCLD preparation).
Biological materials, cross linking agents, and surfactants useful in the current invention are discussed above and are likewise useful here in the SCLD
preparation.
[0083] The SCLD step may be performed at different stages in the methods of the current invention. In an exemplary embodiment, the SCLD step is performed after the SCL step. In another exemplary embodiment, the SCLD
step is performed before the SCL step.
[0084] The SCLD step may also be referred to as a bioburden reduction step.
In an exemplary embodiment, more than one SCLD step is performed. In another exemplary embodiment, two SOLD steps are performed. In an exemplary embodiment where two SCLD steps are performed, the first SCLD
step may be referred to as an initial bioburden reduction step (iBReP) and the second SCLD step may be referred to as a final bioburden reduction step (fBReP).
[0085] A variety of denaturants are useful in the SCLD step of the present invention. In an exemplary embodiment, the denaturant produces a reversible or irreversible loss of higher order structure other than the primary structure of proteins in a biological material. In another exemplary embodiment, the denaturant is a protic solvent useful in removing infectious materials or chemical agents. Protic solvents of use in practicing the present invention include water, alcohols, carboxylic acids, and the like. In another exemplary embodiment, the denaturant is an alcohol or other solvent incorporating an alcohol. The biological material is treated with substantially any amount of alcohol that provides the sought after results.
[0086] The determination of the correct amount of alcohol needed for a particular application is well within the abilities of those of skill in the art. For example, a biological tissue is subjected to one or more SCLD steps and the biological material is collected. The amount of infectious material or chemical agent removed by the SCLD step is determined. When the alcohol ceases to remove infectious agent or chemical agent from the tissue an end point is reached, which is indicative of the amount of alcohol necessary to remove the particular agent from the tissue. In an exemplary embodiment utilizing an alcohol, the tissue is treated with an aqueous alcohol solution containing from about 1% to about 100% alcohol, more preferably from about 10% to about 80% alcohol.
[0087] Exemplary alcohols include one or more compounds of the group consisting of methanol, ethyl alcohol, propyl alcohol, butyl alcohol, pentyl alcohol, hexyl alcohol, heptyl alcohol, octyl alcohol, nonyl alcohol, decyl alcohol, long chain alcohols (e.g. 1,2-octanediol) and the like. In another exemplary embodiment, a method of the present invention uses ethanol. In another exemplary embodiment, the alcohol is isopropyl alcohol.
[0088] As discussed above, a variety of cross linking agents are useful in the methods of the present invention, including the SCLD preparation. In an exemplary embodiment, the SCLD preparation comprises an aldehyde as the cross linking agent. In a further exemplary embodiment, formaldehyde is the cross linking agent. A variety of formaldehyde concentrations are useful in the SCLD preparation. In an exemplary embodiment, the SCLD preparation comprises about 0.5% to about 10% formaldehyde. In another exemplary embodiment, the SCLD preparation comprises about 4% formaldehyde.
(0089] The SCLD preparation may employ any appropriate surfactant. In an exemplary embodiment, the surfactant used in the SCLD preparation is a nonionic surfactant. In another exemplary embodiment, the SCLD preparation comprises Tween 80 as the surfactant. In another exemplary embodiment, the SCLD preparation comprises about 0.5% to about 5% Tween 80. In another exemplary embodiment, the SCLD preparation comprises about 2.1 % of Tween 80.
[0090] In an exemplary embodiment, the SCLD step is performed at a temperature selected to provide optimal calcification mitigation, calcification reduction and/or reduction of phospholipid content of a biological material.
In exemplary embodiment, the SCLD step is performed at approximately a single temperature. In another exemplary embodiment, the SCLD step is performed at more than one temperature.
[0091] In another exemplary embodiment, the SCLD step is performed at approximately room temperature. In another exemplary embodiment, heat is applied to the SCLD preparation. In another exemplary embodiment, the SCLD
step is performed at a temperature between about 30°C and 55°C.
In another exemplary embodiment, the SCLD step is performed between about 30°C and about40°C.
[0092] In another exemplary embodiment, two SCLD steps are preformed: an iBReP step and an fBReP step. In another exemplary embodiment, the iBReP
step is performed at about room temperature and the fBReP step is performed at a temperature above room temperature. In another exemplary embodiment, the fBReP step is performed between about 30°C and about 37°C.
[0093] In another exemplary embodiment, each SCLD step is performed for a time selected to provide optimal calcification mitigation, calcification reduction and/or reduction of phospholipid content of a biological material. In another exemplary embodiment, the iBReP step is performed from about 1 hour to about 4 hours and the fBReP step is performed from about 5 hours to about 15 hours.
5 [0094] In another exemplary embodiment, the SCLD step is performed at a pH selected to provide optimal calcification mitigation, calcification reduction and/or reduction of phospholipid content of a biological material. In another exemplary embodiment, the pH of the SCLD solution is between about 6 and about 8. In another exemplary embodiment, the pH is maintained at about 7.0, 10 7.1,7.2,7.3,7.4,7.5,7.6,7.7,7.8,or7.9.
[0095] The SCLD step can be performed as a single step. Alternatively, the extraction can be performed as a series of sequential steps. At the end of each sequential step, the SCLD preparation is preferably removed prior to contacting the tissue with a new fraction of the SCLD preparation.
15 [0096] In an exemplary embodiment, the SCLD step is performed before the SCL step. In another exemplary embodiment, the SOLD step is performed after the SCL step.
Contacting a Biological Material with a Terminal Liquid Sterilization Solution [0097] In an exemplary embodiment, the methods of the present invention 20 further include contacting the biological tissue with a terminal liquid sterilization solution. Typically, the biological tissue is contacted with a terminal liquid sterilization solution after completion of the SCL and SCLD
steps previously discussed.
[0098] Exemplary terminal liquid sterilization solutions (hereinafter referred 25 to as "TLS" solutions) are capable of sterilizing the biological material before implantation. Sterilants useful in the current invention include cross linking agents, heat, radiation, electron beams, ultraviolet radiation, and combinations thereof. In an exemplary embodiment, the TLS solution comprises heat and a cross linking reagent. Exemplary cross linking agents useful in the TLS
solution are described above.
[0099] In an exemplary embodiment, the TLS solution is heated to a temperature from about 35°C to about 50°C. In another exemplary embodiment, TLS solution is heated to a temperature from about 35°C to about 40°C.
[0100] In another exemplary embodiment, the TLS solution is maintained at a pH between about 6 and 9. In another exemplary embodiment, the TLS
solution is maintained at a pH between about 7.2-7.5.
[0101] In an exemplary embodiment, the TLS solution is contacted with the biological material for sufficient time to sterilize the biological material.
One of skill will recognize that the time required for sterilization will depend on the stringency of the TLS solution. For example, a TLS solution containing an aldehyde that is heated to about 37°C may require 1 to 6 days to sterilize the biological material whereas heating the TLS solution to 50°C may decrease the required time to 25 hours.
[0102] In another exemplary embodiment, the TLS solution comprises about 0.2% to about 2.0% by weight glutaraldehyde.
[0103] In another exemplary embodiment, the terminal sterilization time and temperature is 1-6 days at 37 degrees Celsius. In another particularly preferred embodiment, the terminal sterilization time and temperature is 1-2 days at 50 degrees Celsius. One skilled in the art will recognize that other terminal sterilization times and temperatures may be adjusted while maintaining the effectiveness of the TLS solution.
Contacting a Biological Material with a Cross Linking-A e~nt [0104] In an exemplary embodiment, the methods of the present invention further include contacting the biological tissue with a fixation solution that comprises a cross linking agent in the absence of denaturant. The biological tissue is contacted with the fixation solution before the SCL and SCLD steps, after the SCL and SCLD steps, or between the SCL and SCLD steps. Typically, the biological tissue is contacted with the fixation solution before the SCL
and SCLD steps.
[0105] Fixation solutions useful in the present invention include a cross linking agent to effect crosslinking of the connective tissue proteins within the tissue. Cross linking agents useful in the current invention are discussed above and are likewise useful here in the fixation solution.
[0106] In an exemplary embodiment, the fixation solution contains a cross linking agent at a concentration of about 0.2% to about 2.0 % by weight. In another exemplary embodiment, the cross linking reagent is glutaraldehyde. In another exemplary embodiment, the fixation solution contains glutaraldehyde as the cross linking agent at a concentration of about 0.2% to about 2.0 % by weight.
[0107] In another exemplary embodiment, the fixation solution is contacted with the biological material from about 0.5 hours to about 14 days. In another exemplary embodiment, the fixation solution is contacted with the biological material for about 1-4 days. In another exemplary embodiment, the fixation solution is contacted with the biological material for about 2 days.
[0108] In another exemplary embodiment, the fixation solution further comprises a surfactant. Useful surfactants and surfactant concentrations are described above and are equally applicable to the fixation solution.
[0109] The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding equivalents of the features shown and described, or portions thereof, it being recognized that various modifications are possible within the scope of the invention claimed.
Moreover, any one or more features of any embodiment of the invention may be combined with any one or more other features of any other embodiment of the invention, without departing from the scope of the invention. For example, the surfactants and cross linking agents and respective concentrations described in the SCL step are equally applicable to the SCLD step. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
EXAMPLE S
[0110] Example 1 describes a method of mitigating calcification in pericardial tissue wherein the pericardial tissue is subjected to treatment with a SCL
preparation comprising 10% Tween 80 and 0.625% glutaraldehyde.
1.1. Methods 1.1.1. Post Tween Process Method [0111] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0112] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 30 minutes followed by a 7 day quarantine.
[0113] Remaining leaflets were treated with 0.625% glutaraldehyde and 10%
Tween 80 in aqueous solvent for 7 days. Leaflets were then either subjected to 1 S subsequent steps or implanted subcutaneously into Sprague-Dawley Rats for days, explanted, and submitted for calcium analysis. The leaflets that were implanted into rats are hereinafter referred to in Example 1 as "Post Tween Process" leaflets.
[0114] Remaining leaflets were subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 to 2.5 hours.
[0115] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0116] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a 5 solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 to 37 degrees Celsius for hours ~ 30 minutes.
10 [0117] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
15 [0118] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 35-40°C (measured at representative coolest and 20 warmest product internal location) for 25 - 35C.
[0119] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 1 as "Tween/TLS Process"
leaflets.
1.1.2. Full Process Control Method [0120] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0121] After preparation, the leaflets were chemically fixed by treatment with 0.625% glutaraldehyde in aqueous solvent for 14 days. Leaflets were then either subjected to subsequent steps or implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis. The leaflets that were implanted into rats are hereinafter referred to in Example 1 as "14-day Control" leaflets.
[0122] Remaining leaflets were subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0123] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0124] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours t 30 minutes.
[0125] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0126] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 35 - 40°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours including.
[0127] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 1 as "Full Process Control"
leaflets.
1.1.3. Calcium Analysis [0128] After undergoing one of the four treatments outlined above, leaflets 1 S were implanted subcutaneously into Sprague-Dawley Rats for 90 days. The leaflets were removed and prepared for calcium content analysis.
[0129] Leaflets were first lyophilized and weighed then treated with 70%
Nitric Acid at 110°C until completely digested. The digested samples were brought to a final concentration of 3,000 ppm of KCI.
[0130] The samples were analyzed for calcium content by atomic absorption spectroscopy (AAS).
1.2. Results [0131] Figure 1 shows the total pg Ca/mg dry leaflet tissue for repetitive treatments using the four methods described above: 1) 14-day Control; 2) Full Process Control; 3) Post Tween Process; and 4) Tween/TLS Process. The data in Figure 1 shows a reduction in the average calcium content of the Tween/TLS
Process and the Post Tween Process relative to the Full Process Control and 14-day Control.
[0132] Figure 2 shows a diamond plot representation of the average calcium content decrease data in Figure 1. The top and bottom of the diamonds in Figure 2 form the 95% confidence interval for the means. The small squares are individual data points. The small horizontal lines near the top and bottom of each diamond are overlap lines.
[0133] Table 1 shows the mitigation of calcification using the Post Tween/TLS step relative to the Full Process Control Leaflet tissue samples containing more than 5 pg Ca/mg dry leaflet tissue are calcified.
Table 1 Method No CalcificationCalcificationTotal Samples Full Process59 5 64 Control Post 62 0 62 Tween/TLS
[0134] Table 1 shows that 7.8% of the tissue from the Full Process Control (group 2) calcified while 0% from the Tween/TLS Process group (group 4) calcified.
[0135] Example 2 describes a method of mitigating calcification in porcine heart valve tissue wherein the porcine heart valve tissue is subjected to treatment with a SCL preparation comprising 10% Tween 80 and 0.625%
glutaraldehyde.
2.1. Methods 2.1.1. Post Tween Process Method [0136] Porcine heart valve tissue leaflets were prepared for chemical fixation by standard techniques.
[0137] After preparation of the porcine heart valve tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 7 days.
[0138] Remaining leaflets were treated with 0.625% glutaraldehyde and 10%
Tween 80 in aqueous solvent for 7 days. Leaflets were then either subjected to subsequent steps or implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis. The leaflets that were implanted into rats are hereinafter referred to in Example 2 as "Post Tween Process" leaflets.
[0139] Remaining leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0140] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0141] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters ( 100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for 5 hours t 30 minutes.
[0142] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive 10 cycles of 10 minutes each.
[0143] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
15 Leaflets were treated at 35 - 40°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours including heat up and cool down within 35 - 40°C.
[0144] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium 20 analysis and are hereinafter referred to in Example 2 as "Tween/TLS
Process"
leaflets.
2.1.2. Full Process Control Method [0145] Porcine heart valve leaf tissue were prepared for chemical fixation by standard techniques.
25 [0146] After preparation, the leaflets were chemically fixed by treatment with 0.625% glutaraldehyde in aqueous solvent for 14 days. Leaflets were then either subjected to subsequent steps or implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis. The leaflets that were implanted into rats are hereinafter referred to in Example 2 as "14-day Control" leaflets.
[0147] Remaining leaflets were subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0148] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0149] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours t 30 minutes.
[0150] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0151] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 37.5 ~ 2.5°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours.
[0152] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 2 as "Full Process Control"
leaflets.
2.1.3. Calcium Analysis [0153] After undergoing one of the four treatments outlined above, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days. The leaflets were removed and prepared for calcium content analysis.
[0154] Leaflets were first lyophilized and weighed then treated with 70%
Nitric Acid at 110°C until completely digested. The digested samples were brought to a final concentration of 3,000 ppm of KCI.
[0155] The samples were analyzed for calcium content by atomic absorption spectroscopy (AAS).
2.2. Results [0156] Figure 3 shows the total p,g Ca/mg dry leaflet tissue for repetitive treatments using the four methods described above: 1) 14-day Control; 2) Full Process Control; 3) Post Tween Process; and 4) Tween/TLS Process. The data in Figure 3 shows a reduction in the average calcium content of the Tween/TLS
Process relative to the Full Process Control and 14-day Control.
[0157] Figure 4 shows a diamond plot representation of the average calcium content decrease data in Figure 3. The top and bottom of the diamonds in Figure 2 form the 95% confidence interval for the means. The small squares are individual data points. The small horizontal lines near the top and bottom of each diamond are overlap lines.
S
[0158] Table 2 shows the mitigation of calcification using the Post Tween/TLS step relative to the Full Process Control. Leaflet tissue samples containing more than 5 pg Ca/mg dry leaflet tissue are calcified.
Table 2 Method No CalcificationCalcificationTotal Sam les Full Process28 7 35 Control Post Glut/Tween34 3 37 Full Process Test [0159] Table 2 shows that 20% (7/35) of the tissue from the Full Process Control (group 2) calcified while 8.1% (3/37) from the Tween/TLS Process group (group 4) calcified.
[0160] Example 3 describes a method of mitigating calcification in pericardial tissue wherein the pericardial tissue is subjected to treatment with a SCL
preparation comprising 1.2% Tween 80 and 0.625% glutaraldehyde.
3.1. Methods 3.1.1. Control Group, 14 Day Glutaraldehyde Treated Leaflets [0161] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0162] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 12-24 hours followed by a 14 day quarantine. The samples were then implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis. These samples are hereinafter referred to in Example 3 as "Group 1" leaflets.
3.1.2. Control Group, Fully Processed Leaflets [0163] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0164] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 12-24 hours followed by a 14 day quarantine.
[0165] The leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0166] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0167] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours ~ 30 minutes.
[0168] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0169] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a 5 solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 37.5 ~ 2.5°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours.
[0170] After the TLS procedure, leaflets were implanted subcutaneously into 10 Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred in Example 3 as "Group 2" leaflets.
3.1.3. Test Groun, 14 Day Glutaraldehyde, 7 Day Glutaraldehyde/1.2% Tween-80 Treated Leaflets [0171] Bovine pericardial tissue leaflets were prepared for chemical fixation 15 using standard techniques.
[0172] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 12-24 hours followed by a 7 day quarantine.
Subsequently, the leaflets were treated with 0.625% glutaraldehyde and 1.2%
20 Tween 80 in aqueous solvent for 7 days.
[0173] The leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was 25 equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0174] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0175] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4 Formaldehyde, 22 % ethanol, 1.2 % Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours ~ 30 minutes.
[0176] After treatment, the leaflets were rinsed in 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0177] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 35 - 40°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours.
[0178] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 3 as "Group 3" leaflets.
3.1.4. Test Grouu, 1 Day Glutaraldehyde, 13 Day Glutaraldehyde/1.2% Tween-80 Treated Leaflets [0179] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0180] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 12-24 hours. Subsequently, the leaflets were treated with 0.625% glutaraldehyde and 1.2% Tween 80 in aqueous solvent for 13 days.
[0181] The leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0182] After treatment, the leaflets were rinsed in 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters ( 100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0183] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4 Formaldehyde, 22 % ethanol, 1.2 % Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours ~ 30 minutes.
[0184] After treatment, the leaflets were rinsed in 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0185] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 35 40°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours.
[0186] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 3 as "Group 4" leaflets.
3.1.3. Calcium Analysis [0187] After undergoing one of the four treatments outlined above, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days. The leaflets were removed and prepared for calcium content analysis.
[0188] Leaflets were first lyophilized and weighed then treated with 70%
Nitric Acid at 110°C until completely digested. The digested samples were brought to a final concentration of 3,000 ppm of KCI.
[0189] The samples were analyzed for calcium content by atomic absorption spectroscopy (AAS).
3.2. Results [0190] Table 3 shows the mitigation of calcification using the 7 day Tween 80 test group (group 3) and 13 day Tween 80 test group (group 4) relative to the Full Process Control (group 2). Leaflet tissue samples containing more than S
pg Ca/mg dry leaflet tissue are calcified.
Table 3 Method No Calcification Calcification Total Samples Group 2 90 4 94 Group 3 91 0 91 Group 4 87 2 89 [0191] Table 2 shows that 4.26% (4/94) of the tissue from the Bull Process Control (group 2) calcified while 0.0% (0/91 ) from the 7 day Glutaraldehyde, day Tween 80 test group (group 3) calcified. In addition, only 2.25% of the 1 day Glutaraldehyde, 13 day Tween 80 test group (group 4) showed calcification. Thus, both group 3 and 4 showed a reduction in calcification relative to the Full Process Control groups.
[0192] Example 4 describes a method of reducing phospholipid content in porcine heart valve tissue wherein the porcine heart valve tissue is subjected to treatment with a SCL preparation comprising between 0.6%-6% Tween 80 and 0.625% glutaraldehyde for 7 to 15 days.
4.1. Methods 4.1.1. General Methods [0193] Porcine heart valve tissue leaflets were prepared for chemical fixation by standard techniques.
[0194] After preparation of the porcine heart valve tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 1 to 14 days as shown in Table 4.
[0195] Leaflets were then treated with 0.625% glutaraldehyde and from 0.6%
to 6.0% Tween 80 for 5 to 15 days as shown in Table 4.
[0196] Leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22%
ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets.
Leaflets were treated at room temperature for 2 - 2.5 hours.
[0197] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing 5 solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0198] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a 10 solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours ~ 30 minutes.
1 S [0199] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
20 [0200] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.516 - 0.656 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets. Leaflets were treated at 35 - 40°C (measured at representative coolest 25 and warmest product internal location) for 25 - 35 hours.
4.1.2. Phospholipid Analysis [0201] After undergoing the treatment outlined above, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days. The leaflets were explanted and prepared for phospholipid content analysis.
[0202] Leaflets were frozen liquid in nitrogen, pulverized, and dissolved in extraction solvent containing chloroform and methanol. After addition of physiological saline, the precipitated proteins and bulk tissue were removed by centrifugation. The extracted lipids were then collected from the solvent phase and subjected to thin layer chromatography analysis.
[0203] The selected phospholipids analyzed by TLC were sphingomyelin, phosphatidylcholine, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, and phosphatidic acid.
4.2. Results [0204] Table 4 shows the reduction of phospholipid content in methods using the SCL step relative to the method where no SCL step is performed.
Table 4 Fixation conditionsSCL conditions phospholipid content 0.625% 1.7% Tween; ++
Glutaraldehyde;7days;
7 days 25C
0.625% 1.7% Tween; +++
Glutaraldehyde;7days;
7 days 37C
0.625% 4.9% Tween; +~-+
Glutaraldehyde;7days;
7 days 25C I
0.625% 4.9% Tween; +++
Glutaraldehyde; 7days;
7 days 37C
0.625% 1.7% Tween; +++
Glutaraldehyde; 13 days;
1 day 25C
0.625% 1.7% Tween; ++-+
Glutaraldehyde; 13 days;
1 day 37C
0.625% 4.9% Tween; +++
Glutaraldehyde; 13 days;
1 day 25C
0.625% 4.9% Tween; +++
Glutaraldehyde; 13 days;
1 day 37C
0.625% 3.3% Tween; +~-+
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 5 days;
9 days 3 I C
0.625% 3.3% Tween; -f-~+
Glutaraldehyde; 15 days;
1 day 3 I C
0.625% 0.6% Tween; ++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 6.0% Tween; +++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 25C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 37C
0.625% No SCL Treatment ---Glutaraldehyde;
14 days 0.625% 1.2% Tween; +++
Glutaraldehyde; 7 days;
7 days 25C
+++ represents <0.200 pg PL/mg of dried tissue ++ represents >0.200 pg PL/mg of dried tissue and <0.400 pg PL/mg of dried tissue + represents > 0.400 p.g PL/mg of dried tissue and <1.000 Itg PL/mg of dried tissue --- represents >1.00 pg PL/mg of dried tissue
[0110] Example 1 describes a method of mitigating calcification in pericardial tissue wherein the pericardial tissue is subjected to treatment with a SCL
preparation comprising 10% Tween 80 and 0.625% glutaraldehyde.
1.1. Methods 1.1.1. Post Tween Process Method [0111] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0112] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 30 minutes followed by a 7 day quarantine.
[0113] Remaining leaflets were treated with 0.625% glutaraldehyde and 10%
Tween 80 in aqueous solvent for 7 days. Leaflets were then either subjected to 1 S subsequent steps or implanted subcutaneously into Sprague-Dawley Rats for days, explanted, and submitted for calcium analysis. The leaflets that were implanted into rats are hereinafter referred to in Example 1 as "Post Tween Process" leaflets.
[0114] Remaining leaflets were subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 to 2.5 hours.
[0115] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0116] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a 5 solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 to 37 degrees Celsius for hours ~ 30 minutes.
10 [0117] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
15 [0118] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 35-40°C (measured at representative coolest and 20 warmest product internal location) for 25 - 35C.
[0119] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 1 as "Tween/TLS Process"
leaflets.
1.1.2. Full Process Control Method [0120] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0121] After preparation, the leaflets were chemically fixed by treatment with 0.625% glutaraldehyde in aqueous solvent for 14 days. Leaflets were then either subjected to subsequent steps or implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis. The leaflets that were implanted into rats are hereinafter referred to in Example 1 as "14-day Control" leaflets.
[0122] Remaining leaflets were subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0123] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0124] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours t 30 minutes.
[0125] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0126] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 35 - 40°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours including.
[0127] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 1 as "Full Process Control"
leaflets.
1.1.3. Calcium Analysis [0128] After undergoing one of the four treatments outlined above, leaflets 1 S were implanted subcutaneously into Sprague-Dawley Rats for 90 days. The leaflets were removed and prepared for calcium content analysis.
[0129] Leaflets were first lyophilized and weighed then treated with 70%
Nitric Acid at 110°C until completely digested. The digested samples were brought to a final concentration of 3,000 ppm of KCI.
[0130] The samples were analyzed for calcium content by atomic absorption spectroscopy (AAS).
1.2. Results [0131] Figure 1 shows the total pg Ca/mg dry leaflet tissue for repetitive treatments using the four methods described above: 1) 14-day Control; 2) Full Process Control; 3) Post Tween Process; and 4) Tween/TLS Process. The data in Figure 1 shows a reduction in the average calcium content of the Tween/TLS
Process and the Post Tween Process relative to the Full Process Control and 14-day Control.
[0132] Figure 2 shows a diamond plot representation of the average calcium content decrease data in Figure 1. The top and bottom of the diamonds in Figure 2 form the 95% confidence interval for the means. The small squares are individual data points. The small horizontal lines near the top and bottom of each diamond are overlap lines.
[0133] Table 1 shows the mitigation of calcification using the Post Tween/TLS step relative to the Full Process Control Leaflet tissue samples containing more than 5 pg Ca/mg dry leaflet tissue are calcified.
Table 1 Method No CalcificationCalcificationTotal Samples Full Process59 5 64 Control Post 62 0 62 Tween/TLS
[0134] Table 1 shows that 7.8% of the tissue from the Full Process Control (group 2) calcified while 0% from the Tween/TLS Process group (group 4) calcified.
[0135] Example 2 describes a method of mitigating calcification in porcine heart valve tissue wherein the porcine heart valve tissue is subjected to treatment with a SCL preparation comprising 10% Tween 80 and 0.625%
glutaraldehyde.
2.1. Methods 2.1.1. Post Tween Process Method [0136] Porcine heart valve tissue leaflets were prepared for chemical fixation by standard techniques.
[0137] After preparation of the porcine heart valve tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 7 days.
[0138] Remaining leaflets were treated with 0.625% glutaraldehyde and 10%
Tween 80 in aqueous solvent for 7 days. Leaflets were then either subjected to subsequent steps or implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis. The leaflets that were implanted into rats are hereinafter referred to in Example 2 as "Post Tween Process" leaflets.
[0139] Remaining leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0140] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0141] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters ( 100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for 5 hours t 30 minutes.
[0142] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive 10 cycles of 10 minutes each.
[0143] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
15 Leaflets were treated at 35 - 40°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours including heat up and cool down within 35 - 40°C.
[0144] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium 20 analysis and are hereinafter referred to in Example 2 as "Tween/TLS
Process"
leaflets.
2.1.2. Full Process Control Method [0145] Porcine heart valve leaf tissue were prepared for chemical fixation by standard techniques.
25 [0146] After preparation, the leaflets were chemically fixed by treatment with 0.625% glutaraldehyde in aqueous solvent for 14 days. Leaflets were then either subjected to subsequent steps or implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis. The leaflets that were implanted into rats are hereinafter referred to in Example 2 as "14-day Control" leaflets.
[0147] Remaining leaflets were subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0148] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0149] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours t 30 minutes.
[0150] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0151] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 37.5 ~ 2.5°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours.
[0152] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 2 as "Full Process Control"
leaflets.
2.1.3. Calcium Analysis [0153] After undergoing one of the four treatments outlined above, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days. The leaflets were removed and prepared for calcium content analysis.
[0154] Leaflets were first lyophilized and weighed then treated with 70%
Nitric Acid at 110°C until completely digested. The digested samples were brought to a final concentration of 3,000 ppm of KCI.
[0155] The samples were analyzed for calcium content by atomic absorption spectroscopy (AAS).
2.2. Results [0156] Figure 3 shows the total p,g Ca/mg dry leaflet tissue for repetitive treatments using the four methods described above: 1) 14-day Control; 2) Full Process Control; 3) Post Tween Process; and 4) Tween/TLS Process. The data in Figure 3 shows a reduction in the average calcium content of the Tween/TLS
Process relative to the Full Process Control and 14-day Control.
[0157] Figure 4 shows a diamond plot representation of the average calcium content decrease data in Figure 3. The top and bottom of the diamonds in Figure 2 form the 95% confidence interval for the means. The small squares are individual data points. The small horizontal lines near the top and bottom of each diamond are overlap lines.
S
[0158] Table 2 shows the mitigation of calcification using the Post Tween/TLS step relative to the Full Process Control. Leaflet tissue samples containing more than 5 pg Ca/mg dry leaflet tissue are calcified.
Table 2 Method No CalcificationCalcificationTotal Sam les Full Process28 7 35 Control Post Glut/Tween34 3 37 Full Process Test [0159] Table 2 shows that 20% (7/35) of the tissue from the Full Process Control (group 2) calcified while 8.1% (3/37) from the Tween/TLS Process group (group 4) calcified.
[0160] Example 3 describes a method of mitigating calcification in pericardial tissue wherein the pericardial tissue is subjected to treatment with a SCL
preparation comprising 1.2% Tween 80 and 0.625% glutaraldehyde.
3.1. Methods 3.1.1. Control Group, 14 Day Glutaraldehyde Treated Leaflets [0161] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0162] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 12-24 hours followed by a 14 day quarantine. The samples were then implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis. These samples are hereinafter referred to in Example 3 as "Group 1" leaflets.
3.1.2. Control Group, Fully Processed Leaflets [0163] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0164] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 12-24 hours followed by a 14 day quarantine.
[0165] The leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0166] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0167] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours ~ 30 minutes.
[0168] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0169] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a 5 solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 37.5 ~ 2.5°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours.
[0170] After the TLS procedure, leaflets were implanted subcutaneously into 10 Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred in Example 3 as "Group 2" leaflets.
3.1.3. Test Groun, 14 Day Glutaraldehyde, 7 Day Glutaraldehyde/1.2% Tween-80 Treated Leaflets [0171] Bovine pericardial tissue leaflets were prepared for chemical fixation 15 using standard techniques.
[0172] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 12-24 hours followed by a 7 day quarantine.
Subsequently, the leaflets were treated with 0.625% glutaraldehyde and 1.2%
20 Tween 80 in aqueous solvent for 7 days.
[0173] The leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was 25 equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0174] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0175] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4 Formaldehyde, 22 % ethanol, 1.2 % Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours ~ 30 minutes.
[0176] After treatment, the leaflets were rinsed in 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0177] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 35 - 40°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours.
[0178] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 3 as "Group 3" leaflets.
3.1.4. Test Grouu, 1 Day Glutaraldehyde, 13 Day Glutaraldehyde/1.2% Tween-80 Treated Leaflets [0179] Bovine pericardial tissue leaflets were prepared for chemical fixation using standard techniques.
[0180] After preparation of the bovine pericardial tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 12-24 hours. Subsequently, the leaflets were treated with 0.625% glutaraldehyde and 1.2% Tween 80 in aqueous solvent for 13 days.
[0181] The leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22% ethanol, 1.2% Tween 80, and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at room temperature for 2 - 2.5 hours.
[0182] After treatment, the leaflets were rinsed in 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters ( 100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0183] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4 Formaldehyde, 22 % ethanol, 1.2 % Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours ~ 30 minutes.
[0184] After treatment, the leaflets were rinsed in 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
[0185] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.625 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets.
Leaflets were treated at 35 40°C (measured at representative coolest and warmest product internal location) for 25 - 35 hours.
[0186] After the TLS procedure, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days, explanted, and submitted for calcium analysis and are hereinafter referred to in Example 3 as "Group 4" leaflets.
3.1.3. Calcium Analysis [0187] After undergoing one of the four treatments outlined above, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days. The leaflets were removed and prepared for calcium content analysis.
[0188] Leaflets were first lyophilized and weighed then treated with 70%
Nitric Acid at 110°C until completely digested. The digested samples were brought to a final concentration of 3,000 ppm of KCI.
[0189] The samples were analyzed for calcium content by atomic absorption spectroscopy (AAS).
3.2. Results [0190] Table 3 shows the mitigation of calcification using the 7 day Tween 80 test group (group 3) and 13 day Tween 80 test group (group 4) relative to the Full Process Control (group 2). Leaflet tissue samples containing more than S
pg Ca/mg dry leaflet tissue are calcified.
Table 3 Method No Calcification Calcification Total Samples Group 2 90 4 94 Group 3 91 0 91 Group 4 87 2 89 [0191] Table 2 shows that 4.26% (4/94) of the tissue from the Bull Process Control (group 2) calcified while 0.0% (0/91 ) from the 7 day Glutaraldehyde, day Tween 80 test group (group 3) calcified. In addition, only 2.25% of the 1 day Glutaraldehyde, 13 day Tween 80 test group (group 4) showed calcification. Thus, both group 3 and 4 showed a reduction in calcification relative to the Full Process Control groups.
[0192] Example 4 describes a method of reducing phospholipid content in porcine heart valve tissue wherein the porcine heart valve tissue is subjected to treatment with a SCL preparation comprising between 0.6%-6% Tween 80 and 0.625% glutaraldehyde for 7 to 15 days.
4.1. Methods 4.1.1. General Methods [0193] Porcine heart valve tissue leaflets were prepared for chemical fixation by standard techniques.
[0194] After preparation of the porcine heart valve tissue leaflets, the samples were chemically fixed by immersion into a solution of 0.625% glutaraldehyde in aqueous solvent for 1 to 14 days as shown in Table 4.
[0195] Leaflets were then treated with 0.625% glutaraldehyde and from 0.6%
to 6.0% Tween 80 for 5 to 15 days as shown in Table 4.
[0196] Leaflets were then subjected to an initial bioburden reduction process (iBReP). In the iBReP procedure, leaflets were treated with a solution of formaldehyde-based sterilant. The solution contained 4% Formaldehyde, 22%
ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer. The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets.
Leaflets were treated at room temperature for 2 - 2.5 hours.
[0197] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing 5 solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 3 consecutive cycles of 10 minutes each.
[0198] After the iBReP procedure, leaflets were subjected to a final bioburden reduction process (fBReP). In the fBReP procedure, leaflets were treated with a 10 solution of formaldehyde-based sterilant. The solution contained 4%
Formaldehyde, 22% ethanol, 1.2% Tween 80 and 11.3 mM phosphate buffer.
The volume was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Leaflets were treated at 30 - 37 degrees Celsius for hours ~ 30 minutes.
1 S [0199] After treatment, the leaflets were rinsed in 0.625% glutaraldehyde in phosphate buffer in aqueous solvent at 7.4 pH. The volume of the rinsing solution was equal to or greater than one hundred milliliters (100 ml) of solution per 3 leaflets. Rinsing was performed at room temperature for 4 consecutive cycles of 10 minutes each.
20 [0200] After the fBReP procedure, leaflets were subjected to a terminal liquid sterilization process (TLS). In the TLS procedure, leaflets were treated with a solution of 0.516 - 0.656 % glutaraldehyde in phosphate buffer in aqueous solvent at 7.2-7.5 pH. The volume of the solution was 100 ml of solution per 3 leaflets. Leaflets were treated at 35 - 40°C (measured at representative coolest 25 and warmest product internal location) for 25 - 35 hours.
4.1.2. Phospholipid Analysis [0201] After undergoing the treatment outlined above, leaflets were implanted subcutaneously into Sprague-Dawley Rats for 90 days. The leaflets were explanted and prepared for phospholipid content analysis.
[0202] Leaflets were frozen liquid in nitrogen, pulverized, and dissolved in extraction solvent containing chloroform and methanol. After addition of physiological saline, the precipitated proteins and bulk tissue were removed by centrifugation. The extracted lipids were then collected from the solvent phase and subjected to thin layer chromatography analysis.
[0203] The selected phospholipids analyzed by TLC were sphingomyelin, phosphatidylcholine, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, and phosphatidic acid.
4.2. Results [0204] Table 4 shows the reduction of phospholipid content in methods using the SCL step relative to the method where no SCL step is performed.
Table 4 Fixation conditionsSCL conditions phospholipid content 0.625% 1.7% Tween; ++
Glutaraldehyde;7days;
7 days 25C
0.625% 1.7% Tween; +++
Glutaraldehyde;7days;
7 days 37C
0.625% 4.9% Tween; +~-+
Glutaraldehyde;7days;
7 days 25C I
0.625% 4.9% Tween; +++
Glutaraldehyde; 7days;
7 days 37C
0.625% 1.7% Tween; +++
Glutaraldehyde; 13 days;
1 day 25C
0.625% 1.7% Tween; ++-+
Glutaraldehyde; 13 days;
1 day 37C
0.625% 4.9% Tween; +++
Glutaraldehyde; 13 days;
1 day 25C
0.625% 4.9% Tween; +++
Glutaraldehyde; 13 days;
1 day 37C
0.625% 3.3% Tween; +~-+
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 5 days;
9 days 3 I C
0.625% 3.3% Tween; -f-~+
Glutaraldehyde; 15 days;
1 day 3 I C
0.625% 0.6% Tween; ++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 6.0% Tween; +++
Glutaraldehyde; 10 days;
4 days 31 C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 25C
0.625% 3.3% Tween; +++
Glutaraldehyde; 10 days;
4 days 37C
0.625% No SCL Treatment ---Glutaraldehyde;
14 days 0.625% 1.2% Tween; +++
Glutaraldehyde; 7 days;
7 days 25C
+++ represents <0.200 pg PL/mg of dried tissue ++ represents >0.200 pg PL/mg of dried tissue and <0.400 pg PL/mg of dried tissue + represents > 0.400 p.g PL/mg of dried tissue and <1.000 Itg PL/mg of dried tissue --- represents >1.00 pg PL/mg of dried tissue
Claims (24)
1. A method of treating a biological material comprising the steps of:
(a) contacting the biological material with a preparation comprising a surfactant and a cross linking agent in the absence of a denaturant; and (b) contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant.
(a) contacting the biological material with a preparation comprising a surfactant and a cross linking agent in the absence of a denaturant; and (b) contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant.
2. The method according to claim 1 wherein said method results in mitigating calcification in said biological material when implanted into a host organism relative to the same method that does not include step (a).
3. The method according to claim 2 wherein said mitigating calcification results in elimination of calcification in said biological material.
4. The method according to claim 1 wherein said method results in reducing the phospholipid content in said biological material when implanted into a host organism relative to the same method that does not include step (a).
5. The method according to claim 1 wherein said step (a) is performed prior to said step (b).
6. The method according to claim 1 wherein the method further comprises, after completion of steps (a) and (b), contacting the biological material with a terminal liquid sterilization solution.
7. The method according to claim 6 wherein the method further comprises, prior to step (a), contacting the biological material with a solution comprising a cross linking agent in the absence of a denaturant and in the absence of a surfactant.
8. The method according to claim 1 wherein the biological material is a bioprosthetic tissue.
9. The method according to claim 8 wherein the bioprosthetic tissue is incorporated into a bioprosthesis.
10. The method according to claim 6 wherein the terminal sterilization solution comprises a cross linking agent and is heated to a temperature in the range from 35 to 55 degrees Celsius.
11. The method according to claim 1 wherein the cross linking agent of the preparation used in step (a) and (b) is independently selected form the group consisting of an aldehyde, a diisocyanate, a carbodiimide, a polyepoxy compound, a bifunctional maleimide compound, a bifunctional N-hydroxysuccinimide ester compound, a bifunctional imidoester compound, a bifunctional pyridylthio compound, a bifunctional vinylsulfone compound, a photoactivatable cross-linkers or combination thereof.
12. The method according to claim 11 wherein the cross linking agent of the preparation used in step (a) is glutaraldehyde.
13. The method according to claim 1 wherein the cross linking agent of the preparation used in step (b) is a member selected form the group consisting of formaldehyde, glutaraldehyde or a combination thereof.
14. The method according to claim 1 wherein the denaturant of the preparation used in step (b) is a protic solvent.
15. The method according to claim 14 wherein the denaturant of the preparation used in step (b) is an alcohol.
16. The method according to claim 15 wherein the denaturant of the preparation used in step (b) is ethanol.
17. The method according to claim 1 wherein the surfactant of the preparation used in step (a) is selected from the group consisting of a nonionic surfactant.
18. The method according to claim 17 wherein the surfactant of the preparation used in step (a) is Tween 80.
19. The method according to claim 18 wherein the concentration of Tween 80 in is between 0.7% and 15%.
20. The method according to claim 19 wherein the concentration of Tween 80 is selected between 1.6% and 11%.
21. A method of treating a biological material comprising the steps of:
(a) first contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant;
(b) following step (a), contacting the biological material with a preparation comprising a surfactant and a cross linking agent;
(c) following step (b), contacting the biological material with a preparation comprising surfactant, a cross linking agent and a denaturant; and (d) following step (c), contacting the biological material with a terminal liquid sterilization solution.
(a) first contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant;
(b) following step (a), contacting the biological material with a preparation comprising a surfactant and a cross linking agent;
(c) following step (b), contacting the biological material with a preparation comprising surfactant, a cross linking agent and a denaturant; and (d) following step (c), contacting the biological material with a terminal liquid sterilization solution.
22. The method according to claim 21 wherein said method results in mitigating calcification in said biological material when implanted into a host organism relative to the same method that does not include step (b).
23. The method according to claim 21 wherein said method results in reducing the phospholipid content in said biological material when implanted into a host organism relative to the same method that does not include step (b).
24. A biological material resistant to calcification produced by a method of treating said biological material comprising the steps of:
(a) contacting the biological material with a preparation comprising a surfactant and a cross linking agent in the absence of a denaturant;
and (b) contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant.
(a) contacting the biological material with a preparation comprising a surfactant and a cross linking agent in the absence of a denaturant;
and (b) contacting the biological material with a preparation comprising a surfactant, a cross linking agent and a denaturant.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39687902P | 2002-07-16 | 2002-07-16 | |
US60/396,879 | 2002-07-16 | ||
PCT/US2003/022121 WO2004006974A1 (en) | 2002-07-16 | 2003-07-16 | Enhanced phospholipid reduction and calcification mitigation of biological materials |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2490060A1 true CA2490060A1 (en) | 2004-01-22 |
Family
ID=30116063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002490060A Abandoned CA2490060A1 (en) | 2002-07-16 | 2003-07-16 | Enhanced phospholipid reduction and calcification mitigation of biological materials |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040093674A1 (en) |
EP (1) | EP1531878A1 (en) |
JP (1) | JP2005532877A (en) |
AU (1) | AU2003249272A1 (en) |
BR (1) | BR0305562A (en) |
CA (1) | CA2490060A1 (en) |
WO (1) | WO2004006974A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7955788B2 (en) * | 2003-10-30 | 2011-06-07 | Medtronic, Inc. | Bioprosthetic tissue preparation with synthetic hydrogels |
US7422607B2 (en) * | 2004-08-24 | 2008-09-09 | Oviatt Henry W | Anti-calcification treatments for heart valves and vascular grafts |
US20060110370A1 (en) * | 2004-11-23 | 2006-05-25 | Pathak Chandrashenkhar P | Treatments for reduction of cytotoxicity and viral contamination of implantable medical devices |
US7989157B2 (en) * | 2005-01-11 | 2011-08-02 | Medtronic, Inc. | Solution for storing bioprosthetic tissue used in a biological prosthesis |
FR2951549B1 (en) * | 2009-10-15 | 2013-08-23 | Olivier Schussler | PROCESS FOR OBTAINING IMPLANTABLE MEDICAL BIOPROTHESES |
EP2608815B1 (en) | 2010-08-24 | 2018-03-21 | Collagen Solutions NZ Limited | Biomaterials with enhanced properties and devices made therefrom |
US20220176018A1 (en) * | 2019-04-10 | 2022-06-09 | Meril Life Sciences Pvt Ltd | A process for prevention of degradation and degeneration of tissue used in bioprosthesis |
CN110339400A (en) * | 2019-08-07 | 2019-10-18 | 太仓新亚逊生物科技有限公司 | The anticalcium processing method of biomaterial |
CN117899269A (en) * | 2022-10-12 | 2024-04-19 | 上海微创心通医疗科技有限公司 | Anti-calcification method of bioprosthetic tissue and bioprosthetic tissue |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59502104A (en) * | 1982-11-12 | 1984-12-20 | バスクー インターナショナル インコーポレーテッド | Treatment with surfactants to inhibit calcium deposition in transplantable biological tissues |
WO1984001879A1 (en) * | 1982-11-12 | 1984-05-24 | American Hospital Supply Corp | Surfactant treatment of implantable biological tissue to inhibit calcification |
EP0458877B1 (en) * | 1989-02-17 | 1995-05-17 | Baxter International Inc. | Calcification mitigation of bioprosthetic implants |
JPH04288165A (en) * | 1991-03-18 | 1992-10-13 | Terumo Corp | Organ implant and manufacture thereof |
US5931969A (en) * | 1994-07-29 | 1999-08-03 | Baxter International Inc. | Methods and apparatuses for treating biological tissue to mitigate calcification |
US6214054B1 (en) * | 1998-09-21 | 2001-04-10 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
BR0115106A (en) * | 2000-11-01 | 2006-02-21 | Edwards Lifesciences Corp | methods for preparing bioprosthetic tissue and implantable devices comprising such bioprosthetic tissue |
US20030050276A1 (en) * | 2001-08-15 | 2003-03-13 | Cunanan Crystal M. | Treatment of tissue, instruments and work surfaces to remove infectious agents |
-
2003
- 2003-07-16 AU AU2003249272A patent/AU2003249272A1/en not_active Abandoned
- 2003-07-16 EP EP03764694A patent/EP1531878A1/en not_active Withdrawn
- 2003-07-16 JP JP2004521862A patent/JP2005532877A/en active Pending
- 2003-07-16 WO PCT/US2003/022121 patent/WO2004006974A1/en not_active Application Discontinuation
- 2003-07-16 BR BR0305562-0A patent/BR0305562A/en not_active IP Right Cessation
- 2003-07-16 CA CA002490060A patent/CA2490060A1/en not_active Abandoned
- 2003-07-16 US US10/620,712 patent/US20040093674A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003249272A1 (en) | 2004-02-02 |
BR0305562A (en) | 2004-09-28 |
EP1531878A1 (en) | 2005-05-25 |
US20040093674A1 (en) | 2004-05-20 |
JP2005532877A (en) | 2005-11-04 |
WO2004006974A1 (en) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1098670B1 (en) | Crosslinking of bioprosthetic material to mitigate post-implantation calcification | |
JP4555570B2 (en) | Treatment of bioprosthetic tissue to reduce post-transplant calcification | |
US6008292A (en) | Method for inhibiting calcification of aldehyde-fixed bioprosthetic materials | |
JP3797673B2 (en) | Method for treating implantable biological tissue to reduce calcification and bioprosthesis treated in such a manner | |
US20200353126A1 (en) | Sterilization Process | |
US20060217804A1 (en) | Treatment of bioprosthetic tissues to mitigate post implantation calcification | |
US5882850A (en) | Method for reducing calcification of biological tissue used implantable bioprostheses | |
JP2022519407A (en) | How to Prepare Living Tissue for Surgical Transplantation | |
US20040093674A1 (en) | Enhanced phospholipid reduction and calcification mitigation of biological materials | |
WO2013060103A1 (en) | Method for treating animal-derived collagen fibre materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20090716 |